Australian Broker Call
Produced and copyrighted by
at www.fnarena.com
August 21, 2026
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1).
Last Updated: 03:01 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
| BGA - | Bega Cheese | Downgrade to Hold from Accumulate | Morgans |
| CWY - | Cleanaway Waste Management | Downgrade to Equal-weight from Overweight | Morgan Stanley |
| GMG - | Goodman Group | Downgrade to Hold from Buy | Bell Potter |
| HSN - | Hansen Technologies | Downgrade to Underweight from Overweight | Morgan Stanley |
| MP1 - | Megaport | Upgrade to Overweight from Equal-weight | Morgan Stanley |
| NST - | Northern Star Resources | Downgrade to Hold from Accumulate | Morgans |
| SHL - | Sonic Healthcare | Downgrade to Hold from Buy | Morgans |
| SUL - | Super Retail | Upgrade to Buy from Hold | Ord Minnett |
| TPW - | Temple & Webster | Downgrade to Hold from Buy | Bell Potter |
| VCX - | Vicinity Centres | Downgrade to Neutral from Buy | UBS |
| WHC - | Whitehaven Coal | Downgrade to Hold from Buy | Morgans |
Overnight Price: $0.26
UBS rates A1N as Sell (5) -
First take: ARN Media's H1 topline and EBITDA are labelled "soft", missing UBS' and consensus forecasts by respectively -7% and -24%.
Commentary blames a decline in metro radio revenue share from the impact of the breakfast show coupled with a strong pcp supported by the Federal election.
Management expects broadly flat FY26 audio revenue, with digital growth and $55m of cumulative cost savings offsetting continuing radio weakness.
UBS retains Sell, with audience-share recovery and the talent reset the potential catalysts, while further advertising and market-share deterioration remain the principal risks. Target 20c.
Target price is $0.20 Current Price is $0.25 Difference: minus $0.05 (current price is over target).
If A1N meets the UBS target it will return approximately minus 20% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $0.32, suggesting upside of 26.7% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 5.9, implying annual growth of 278.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 4.2. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 7.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.2, implying annual growth of 5.1%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 4.0. |
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AAI ALCOA CORPORATION
Aluminium, Bauxite & Alumina
More Research Tools In Stock Analysis - click HERE
Overnight Price: $72.91
Citi rates AAI as Buy (1) -
Citi views potentially lower US tariffs on Canadian aluminium as positive for Alcoa, though benefits could be partly offset by a lower Midwest Premium (MWP).
Reducing Section 232 tariffs to 25% from 50% could lower annual tariff costs by around $500m, the analyst explains, equivalent to 17% of 2027 consensus earnings (EBITDA).
Alcoa currently benefits from a US$1.12/lb MWP, with every US$0.25/lb movement worth around US$500m in revenue, the broker notes.
The potential tariff change is expected to be supportive but not overwhelmingly positive given uncertainty around deal terms and the MWP response.
Buy rated on Alcoa. Target US$76.
Current Price is $71.69. Target price not assessed.
Current consensus price target is $95.00, suggesting upside of 32.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 58.29 cents and EPS of 855.44 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 899.8, implying annual growth of N/A. Current consensus DPS estimate is 55.8, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is 8.0. |
Forecast for FY27:
Current consensus EPS estimate is 941.7, implying annual growth of 4.7%. Current consensus DPS estimate is 55.8, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is 7.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.60
Citi rates AFG as Neutral (3) -
Citi highlights from Australian Finance Group's FY26 results increasing income diversity and resilience, though the housing slowdown remains a near-term headwind.
Profit rose 39% on the prior year, partly supported by one-off income, the analyst explains, while new housing flows declined around -16%.
Citi retains its FY27 lodgement forecast for a -15% year-on-year decline and raises FY27-FY28 EPS forecasts by 3%-4% on stronger lending income. Lodgements refers to the value of home-loan applications that AFG's mortgage brokers submit to lenders.
The broker lowers its target to $1.73 from $1.83 and retains a Neutral rating due to lower peer multiples.
Target price is $1.73 Current Price is $1.60 Difference: $0.13
If AFG meets the Citi target it will return approximately 8% (excluding dividends, fees and charges).
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates AFG as Outperform (1) -
Australian Finance Group reported earnings growth in FY26, with underlying group profit up 33%, driven by the Manufacturing segment (up 86%). Manufacturing segment performance reflected AFG loan book growth of 30% margin of 125bps, up 9bps year on year.
Residential lodgement activity has moderated year on year, down -16%, Macquarie notes. The Investor segment is down -18%, Owner Occupier segment down -14% and the AFG Securities product is down -13%.
Macquarie retains Outperform, noting AFG's securitisation loan book growth continues to support the outlook for earnings, despite mortgage sector headwinds. Target rises to $2.35 from $2.26.
Target price is $2.35 Current Price is $1.60 Difference: $0.75
If AFG meets the Macquarie target it will return approximately 47% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 10.30 cents and EPS of 20.60 cents. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 10.90 cents and EPS of 21.70 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AIA AUCKLAND INTERNATIONAL AIRPORT LIMITED
Travel, Leisure & Tourism
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.29
Citi rates AIA as Neutral (3) -
In the wake of Auckland International Airport's FY26 result, Citi raises its target to NZ$9.00 from NZ$8.80. Neutral rating maintained.
The broker sees an attractive long-term recovery story, though near-term uncertainty and a demanding valuation temper upside.
First Take: Citi highlights a strong start to FY27 for Auckland International Airport, with July international passengers rising 5% year-on-year.
International growth was supported by US and Chinese passengers, while domestic traffic fell -2% and remains -13% below pre-Covid levels, the analysts explain.
The broker forecasts FY27 international passenger growth of around 3% and a -2% domestic decline, with new passenger and EPS guidance due at FY26 results.
Citi likes the medium-term earnings potential from Auckland Airport's -NZ$6bn-plus capex program but sees near-term risks from Air New Zealand ((AIZ)) capacity and weaker economic sentiment.
Current Price is $7.20. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 12.15 cents and EPS of 15.97 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of N/A. Current consensus DPS estimate is 11.4, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 45.9. |
Forecast for FY28:
Current consensus EPS estimate is 17.7, implying annual growth of 12.7%. Current consensus DPS estimate is 12.8, implying a prospective dividend yield of 1.8%. Current consensus EPS estimate suggests the PER is 40.7. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates AIA as Outperform (1) -
Auckland International Airport's underlying NPAT of $309m was 1% ahead of Macquarie's estimate. Normalised EBITDAFI rose 6%.
Softer domestic traffic and commercial forecasts are leading to reduced forecasts.
All in all, Macquarie argues the airport delivered a resilient FY26 result despite slowing passenger momentum, retail disruption and rising depreciation.
Outperform. Target remains NZ$9.31.
Current Price is $7.20. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 11.30 cents and EPS of 15.55 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of N/A. Current consensus DPS estimate is 11.4, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 45.9. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 13.08 cents and EPS of 18.01 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.7, implying annual growth of 12.7%. Current consensus DPS estimate is 12.8, implying a prospective dividend yield of 1.8%. Current consensus EPS estimate suggests the PER is 40.7. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates APA as Buy (1) -
Citi assesses "solid" FY26 results for APA Group, with growth spending and potential Beetaloo Basin and data centre opportunities supporting longer-term upside.
Earnings (EBITDA) rose 8.5% on the prior year, while targeted cost savings doubled to $100m and helped lift margins to 78%, the analyst explains.
The group's -$3.5bn three-year organic capex pipeline is expected to support accelerating earnings and distribution growth through FY29. The broker also forecasts free cash flow (FCF) growth to remain at 3%-4% through FY30.
Buy rating. Target $11.10.
Target price is $11.10 Current Price is $10.52 Difference: $0.58
If APA meets the Citi target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $9.68, suggesting downside of -8.0% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 22.7, implying annual growth of 28.4%. Current consensus DPS estimate is 59.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 46.3. |
Forecast for FY28:
Current consensus EPS estimate is 24.1, implying annual growth of 6.2%. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 43.7. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates APA as Outperform (1) -
APA Group's FY26 underlying earnings were in line with consensus and in the upper half of guidance. FY27 guidance is consistent with Macquarie's forecast and balance sheet capacity is material to fund growth projects.
The opportunity set for growth continues to broaden, with APA expanding its three-year growth capex spend by $0.5bn to $3.5bn, with much of the spend in FY27 and FY28.
APA's enterprise to earnings multiple of 11.5x is attractive compared to the historical range of 11.2-14.2x, Macquarie notes. Federal government policy is favouring gas again, creating the opportunity for sustained growth, with improving balance sheet capacity.
Target rises to $10.50 from $10.41, Outperform retained.
Target price is $10.50 Current Price is $10.52 Difference: minus $0.02 (current price is over target).
If APA meets the Macquarie target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $9.68, suggesting downside of -8.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 59.00 cents and EPS of 21.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.7, implying annual growth of 28.4%. Current consensus DPS estimate is 59.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 46.3. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 60.00 cents and EPS of 22.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.1, implying annual growth of 6.2%. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 43.7. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates APA as Lighten (4) -
Ord Minnett maintains APA Group on Lighten and raises its target to $9.10 from $8.30, after FY26 underlying EBITDA rose 8% to $2.2bn.
The broker sees support from $100m of annualised cost savings and a $3.5bn organic development pipeline, but believes the valuation already recognises this growth.
FY27-FY28 EBITDA forecasts rise 2%.
Target price is $9.10 Current Price is $10.52 Difference: minus $1.42 (current price is over target).
If APA meets the Ord Minnett target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $9.68, suggesting downside of -8.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 59.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.7, implying annual growth of 28.4%. Current consensus DPS estimate is 59.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 46.3. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 60.00 cents and EPS of 24.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.1, implying annual growth of 6.2%. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 43.7. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates APA as Sell (5) -
On further inspection, the target price is raised to $8.50 from $8, with a Sell rating retained.
The broker remains optimistic about APA's potential growth opportunities in the Beetaloo Basin, although commerciality remains unproven and competition for new infrastructure is expected.
EPS forecasts are raised 5% for FY27, tweaked lower for FY28, and raised 13% for FY29. The analyst suggests contracting pressures may be emerging as indicated by a decline in EBITDA in real terms, as the assets have CPI escalation contracts.
UBS maintains a Sell rating for APA Group with an unchanged price target of $8.00 following an in-line FY26 result featuring improved underlying EBITDA of $2,183m and disciplined cost management.
Underlying NPAT of $247m missed UBS estimates due to higher depreciation and amortisation alongside elevated interest costs.
Management guided FY27 EBITDA to $2,260m-$2,340m and lifted organic growth capital expenditure to $3.5bn across FY27-FY29, while highlighting growing contracting pressures across parts of the East Coast grid.
The stock trades on a net debt to EBITDA of 6.1x with forecast dividends per share guided higher to 59.0c.
Target price is $8.50 Current Price is $10.52 Difference: minus $2.02 (current price is over target).
If APA meets the UBS target it will return approximately minus 19% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $9.68, suggesting downside of -8.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 60.00 cents and EPS of 28.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.7, implying annual growth of 28.4%. Current consensus DPS estimate is 59.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 46.3. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 61.00 cents and EPS of 26.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.1, implying annual growth of 6.2%. Current consensus DPS estimate is 60.3, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 43.7. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates ARF as Neutral (3) -
First take: Arena REIT's FY26 operating EPS increased 5.7% to 19.6c and distributions rose 5.5% to 19.25c, broadly matching expectations.
UBS highlights FY27 distribution guidance of at least 18c was below market forecasts because no income is assumed from Edge Early Learning, whose properties were written down by -10%, or -$24.4m.
UBS retains Neutral, balancing full occupancy, 4% rental growth and low gearing against elevated tenant concentration and uncertainty surrounding the Edge portfolio.
Target price is $2.71 Current Price is $2.49 Difference: $0.22
If ARF meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $3.06, suggesting upside of 22.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 19.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.7, implying annual growth of -5.7%. Current consensus DPS estimate is 19.2, implying a prospective dividend yield of 7.7%. Current consensus EPS estimate suggests the PER is 12.6. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 20.00 cents and EPS of 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.3, implying annual growth of 3.0%. Current consensus DPS estimate is 19.9, implying a prospective dividend yield of 8.0%. Current consensus EPS estimate suggests the PER is 12.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
ASG AUTOSPORTS GROUP LIMITED
Automobiles & Components
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.50
Macquarie rates ASG as Outperform (1) -
Autosports Group reported an FY26 result in line with previously downgraded guidance. Revenue growth of 11% year on year was in line with consensus and profit was at the top end of guidance.
Macquarie suggests the stock may struggle to re-rate until supply constraints ease. The last two-months of auto data are showing green shoots.
Catalysts for an inflection point to weak trading are consumer pressures abating and European EV supply constraints into Australia easing, along with Interest rates falling, helping demand and reducing Autosports's finance costs.
Strong EV demand supports improved FY27 visibility as orders convert to deliveries; Macquarie notes, however, recent rate rises, tax policy changes, and weaker ICE demand create some downside risk to revenue/margins.
On valuation, the broker retains Outperform and a $2.50 target.
Target price is $2.50 Current Price is $1.49 Difference: $1.01
If ASG meets the Macquarie target it will return approximately 68% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 9.00 cents and EPS of 19.50 cents. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 10.80 cents and EPS of 23.40 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AVH AVITA MEDICAL INC
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.82
Bell Potter rates AVH as Speculative Buy (1) -
Bell Potter observes Avita Medical announced positive results from a 40-patient clinical trial comparing PermeaDerm with cadaveric allograft for temporary wound treatment before final closure.
PermeaDerm is reducing treatment costs by -70% and preparation time by -96% while achieving comparable clinical outcomes.
The broker notes PermeaDerm remains a modest revenue contributor, but alongside Cohealyx broadens the acute wound care offering and provides meaningful scope to deepen portfolio penetration across existing hospital accounts.
As 2025 reimbursement and execution issues recede, revenue growth re-accelerates and cash consumption moderates, the analyst sees scope for further re-rating, although debt and liquidity remain key constraints.
A lower cost of capital raises the target to $3.70 from $2.10. Speculative Buy rating retained.
Target price is $3.70 Current Price is $2.79 Difference: $0.91
If AVH meets the Bell Potter target it will return approximately 33% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY26:
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 103.32 cents. |
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 9.91 cents. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.79
Citi rates AX1 as Neutral (3) -
First Take: Accent Group's FY26 operating performance was stronger than the headline result suggests, Citi comments, with EBIT before goodwill impairment of $82.6m ahead of consensus and operating EBIT excluding bid defence costs above guidance.
Citi sees FY27 earnings supported by self-help initiatives, including $10m-$20m of FX benefits, around $10m from TAF reacquisitions, store optimisation and new stores, plus $10m-$15m of net cost savings, suggesting consensus EBIT of $95m may be materially too low.
However, like-for-like sales remain weak, down 2% y/y in the first seven weeks, and uncertainty remains over how much of the FX benefit will need to be reinvested in promotions.
Neutral rating. Target 65c.
Target price is $0.65 Current Price is $0.73 Difference: minus $0.075 (current price is over target).
If AX1 meets the Citi target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $0.73, suggesting upside of 1.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Current consensus EPS estimate is 6.2, implying annual growth of -38.7%. Current consensus DPS estimate is 4.2, implying a prospective dividend yield of 5.8%. Current consensus EPS estimate suggests the PER is 11.8. |
Forecast for FY27:
Current consensus EPS estimate is 7.5, implying annual growth of 21.0%. Current consensus DPS estimate is 4.8, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 9.7. |
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.66
Bell Potter rates BGA as Buy (1) -
Bega Cheese's FY26 underlying EBITDA of $225.6m was up 12% and in line with expectations and guidance, while underlying NPAT rose 36%.
The analyst points to 13% growth in branded categories, market share gains in grocery, higher milk supply and a 38% increase in Bulk EBITDA as key positives.
FY27 EBITDA guidance of $240m-$245m brackets consensus but is below the broker's prior $249m forecast, with growth largely dependent on $38m of cost reductions already implemented.
FY27-FY28 NPAT forecasts are broadly unchanged, while the broker retains its Buy rating and raises the target to $8.05 from $7.75 due to lower net debt.
Target price is $8.05 Current Price is $6.49 Difference: $1.56
If BGA meets the Bell Potter target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $6.78, suggesting upside of 4.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 16.00 cents and EPS of 25.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of 42.1%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 25.5. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 19.00 cents and EPS of 27.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 28.5, implying annual growth of 11.8%. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 22.8. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates BGA as Downgrade to Hold from Accumulate (3) -
Morgans moves its recommendation for Bega Cheese to a Hold from an Accumulate rating and increases its price target to $7.05 from $6.50 following a FY26 result that landed at the higher end of guidance.
Sales increased by 6.7% while underlying EBITDA rose 11.7% to $225.6m, driven by strong growth in the Bulk division and robust performance across iconic household brands.
Management guided to FY27 normalised EBITDA of $240m to $245m and reiterated longer-term growth targets supporting a solid earnings profile.
Following strong share price performance, the stock is viewed as fully valued, prompting the downgrade to Hold.
Target price is $7.05 Current Price is $6.49 Difference: $0.56
If BGA meets the Morgans target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $6.78, suggesting upside of 4.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 17.00 cents and EPS of 25.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of 42.1%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 25.5. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 19.50 cents and EPS of 29.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 28.5, implying annual growth of 11.8%. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 22.8. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates BGA as Hold (3) -
Ord Minnett maintains its Hold rating for Bega Cheese and raises its target to $6.30 from $5.70, up 10.5%, after FY26 normalised NPAT increased 35.8% to $69m.
FY27 EBITDA guidance of $240m-$245m is in line with the broker's forecast, supported by branded products, protein demand, international sales and restructuring savings.
Target price is $6.30 Current Price is $6.49 Difference: minus $0.19 (current price is over target).
If BGA meets the Ord Minnett target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $6.78, suggesting upside of 4.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 15.50 cents and EPS of 24.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of 42.1%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 25.5. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 16.50 cents and EPS of 27.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 28.5, implying annual growth of 11.8%. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 22.8. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $18.80
Citi rates BXB as Buy (1) -
Following FY26 results, Citi remains cautiously optimistic on Brambles despite larger-than-expected 1H27 capacity constraint costs and a more second-half-weighted recovery.
FY26 earnings (EBIT) growth of 4% on constant currency was broadly in line with management's 3%-5% guidance, the analyst explains.
The broker considers execution risk manageable as most remediation actions involve routine pallet purchases and service centre rollouts.
Long-term value drivers, including S+ and margin targets, remain on track. S+ refers to "Shaping Our Future+", Brambles' multi-year transformation and investment program.
Citi retains a Buy rating. The target falls by -10c to $22.75.
Target price is $22.75 Current Price is $19.08 Difference: $3.67
If BXB meets the Citi target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $21.38, suggesting upside of 12.0% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 114.1, implying annual growth of N/A. Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Current consensus EPS estimate is 128.1, implying annual growth of 12.3%. Current consensus DPS estimate is 91.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates BXB as Neutral (3) -
Brambles reported FY26 sales of US$7,043m, up 6%, and underlying earnings of US$1,494m, up 9%, despite a -US$90m impact from US repair constraints, Macquarie reports.
Europe/Middle East/Africa and Asia-Pacific delivered solid growth, while Americas earnings were constrained by repair centre disruption, with risks lingering.
Timely resolution of US repair constraints remains key, Macquarie suggests, including restoring customer relationships and new business momentum.
The macro context is also not supportive. The stock trades at a -3% discount to its 10-year average enterprise multiple, which the broker does not think is sufficiently attractive to mitigate the risks. Neutral retained, target rises to $19.00 from $18.60.
Target price is $19.00 Current Price is $19.08 Difference: minus $0.08 (current price is over target).
If BXB meets the Macquarie target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $21.38, suggesting upside of 12.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 67.18 cents and EPS of 101.87 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.1, implying annual growth of N/A. Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 61.21 cents and EPS of 101.72 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.1, implying annual growth of 12.3%. Current consensus DPS estimate is 91.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates BXB as Hold (3) -
Morgans maintains a Hold rating for Brambles with its target price adjusted slightly to $18.60 from $18.70 following a FY26 financial result that was broadly in line with expectations and management guidance.
Revenue increased 6% to US$7,043m while underlying EBIT rose 9% to US$1,494m, driven by price realisation and net new business wins that more than offset softer like-for-like volumes.
Management guided to FY27 constant FX revenue growth of 2%-4% and underlying EBIT growth of 2%-6%, with earnings skewed towards the second half as US repair capacity constraints impact performance in the first half.
Trading on an elevated price-to-earnings multiple with a modest dividend yield, the stock is viewed as fully valued by the broker.
Target price is $18.60 Current Price is $19.08 Difference: minus $0.48 (current price is over target).
If BXB meets the Morgans target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $21.38, suggesting upside of 12.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 96.33 cents and EPS of 107.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.1, implying annual growth of N/A. Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 106.24 cents and EPS of 121.98 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.1, implying annual growth of 12.3%. Current consensus DPS estimate is 91.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates BXB as Buy (1) -
Ord Minnett maintains Brambles on Buy and lowers its target to $24.40 from $24.50, viewing US pallet-repair constraints as temporary.
FY26 underlying EBIT rose 4% to US$1.5bn, but repair issues cost -US$90m and are expected to reduce FY27 earnings by another -US$33m-US$55m before being resolved by the end of the first half.
FY27 EPS is unchanged and FY28 EPS falls circa -2%.
Target price is $24.40 Current Price is $19.08 Difference: $5.32
If BXB meets the Ord Minnett target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $21.38, suggesting upside of 12.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 103.47 cents and EPS of 157.39 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.1, implying annual growth of N/A. Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 118.04 cents and EPS of 177.79 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.1, implying annual growth of 12.3%. Current consensus DPS estimate is 91.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates BXB as Buy (1) -
Brambles' FY26 EBIT of US$1.49bn was in line with UBS and 1% above consensus, despite US repair capacity disruption costs of -US$90m being higher than the -US$60m previously expected.
FY27 guidance is for 2%-4% sales growth and 2%-6% EBIT growth, with a further -US$45m incremental US disruption impact expected, primarily in 1H27, before initiatives begin to provide relief in 2H27.
UBS conservatively assumes US$80m of disruption-related EBIT recovery in FY28, versus around US$110m implied by management, and sees investors potentially waiting for evidence of a strong 2H27 before the shares fully re-rate.
The broker maintains its Buy rating and raises the target to $24.50 from $24.30.
Target price is $24.50 Current Price is $19.08 Difference: $5.42
If BXB meets the UBS target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $21.38, suggesting upside of 12.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 64.00 cents and EPS of 106.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.1, implying annual growth of N/A. Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 84.00 cents and EPS of 120.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.1, implying annual growth of 12.3%. Current consensus DPS estimate is 91.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.62
Bell Potter rates CCL as Buy (1) -
Bell Potter notes Cuscal's FY26 underlying NPAT rose 20% y/y and came in ahead of the implied guidance, while underlying pre-AASB16 EBITDA of $76.1m also exceeded the broker's forecast.
The analyst points to volume growth of 12%, contributions from the Indue and Paymark acquisitions and $2.1m of post-tax synergies in 2H26 as positive earnings drivers with further synergy benefits expected in FY27.
FY27 guidance is for mid-20% volume and underlying NPAT growth, with the broker noting this implies organic growth above 10% and expressing high confidence in the outlook.
Buy rating retained and the target rises to $6.50 from $5.80. The valuation is starting to reflect acquisition synergies, the broker comments.
Target price is $6.50 Current Price is $5.92 Difference: $0.58
If CCL meets the Bell Potter target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $6.25, suggesting upside of 5.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 11.10 cents and EPS of 28.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 28.8, implying annual growth of 30.3%. Current consensus DPS estimate is 13.5, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 20.6. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 9.70 cents and EPS of 33.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 34.4, implying annual growth of 19.4%. Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 17.2. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates CCL as Buy (1) -
Says Ord Minnett: "If you buy Cuscal shares today, you are buying a defensive 3-year forward earnings growth story".
In response to FY26 financials, Ord Minnett maintains its Buy rating and raises its target to $6.44 from $5.51, up 16.9%, after FY26 underlying NPAT increased 20% to $46.2m and exceeded expectations.
The broker forecasts a three-year EPS CAGR of 22%, with ASX300 inclusion and Indue synergies providing catalysts, although commentary does acknowledge the valuation now requires successful delivery.
FY27 EPS rises 1% and FY28 EPS falls -0.5%. Execution and possible shareholder sell-downs have been identified as the main risks.
Target price is $6.44 Current Price is $5.92 Difference: $0.52
If CCL meets the Ord Minnett target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $6.25, suggesting upside of 5.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 13.50 cents and EPS of 29.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 28.8, implying annual growth of 30.3%. Current consensus DPS estimate is 13.5, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 20.6. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 17.00 cents and EPS of 35.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 34.4, implying annual growth of 19.4%. Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 17.2. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $48.88
UBS rates CDA as Neutral (3) -
Codan delivered a record result, with Communications and Metal Detection EBIT exceeding UBS forecasts by 6% and 3%, respectively.
The Communications order book increased 50% to approximately $380m, prompting EPS upgrades of 18% for FY27, 20% for FY28 and 26% for FY29.
UBS sees further upside from defence, public-safety communications, gold demand and acquisitions, but retains Neutral because the shares trade around 40 times FY27 earnings after a strong rally.
Target shifts to $48. Neutral.
First take: UBS maintains a Neutral rating for Codan with an unchanged price target of $42.50 following a strong FY26 result where top-line revenue and EBIT came in 3% and 4% ahead of consensus respectively.
The company reported a 69% increase in net profit after tax to $175m, driven by robust communications segment performance and accelerating earnings momentum within the metal detection division.
Management points to communications revenue growth of 20% into FY27 alongside strong order momentum, while operating cash flow surged 70% to $249m.
The broker's estimates reflect ongoing positive momentum across both core operating segments heading into FY27.
Target price is $48.00 Current Price is $49.02 Difference: minus $1.02 (current price is over target).
If CDA meets the UBS target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $44.45, suggesting downside of -9.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 61.00 cents and EPS of 122.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 108.5, implying annual growth of 12.4%. Current consensus DPS estimate is 51.9, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 45.2. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 69.00 cents and EPS of 140.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 140.0, implying annual growth of 29.0%. Current consensus DPS estimate is 69.0, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 35.0. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $22.11
Citi rates CHC as Buy (1) -
First take: It is Citi's initial assessment that Charter Hall released a strong FY26 result, with operating earnings of $488.1m (up 26.6% YoY) and EPS of 103.2c, aligning with consensus and slightly beating Citi's 102.8c estimate.
Real estate FUM reached $76bn, ahead of Citi's $75.3bn forecast, supported by record gross equity inflows of $6.7bn and property transactions of $17.1bn.
FY27 guidance looks slightly below expectations (by -1%-2%) but Citi adds no performance fees are included. Conclusion: guidance looks conservative.
Target $26.50. Buy.
Target price is $26.50 Current Price is $20.71 Difference: $5.79
If CHC meets the Citi target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $24.97, suggesting upside of 20.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 50.70 cents and EPS of 102.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 103.1, implying annual growth of 116.0%. Current consensus DPS estimate is 50.8, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 20.1. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 53.70 cents and EPS of 116.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 113.4, implying annual growth of 10.0%. Current consensus DPS estimate is 53.8, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 18.3. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates CHC as Buy (1) -
First take: Charter Hall's FY26 operating EPS rose 26.8% to 103.2c, supported by $6.1bn of net acquisitions, $4.5bn of net equity inflows and a 52% increase in development earnings.
UBS comments FY27 guidance for 114c implies 10.5% growth and sits modestly below consensus, although Charter Hall's initial guidance is historically always conservative.
Buy is retained, with transaction activity, capital inflows and the $5.5bn living and mixed-use pipeline offering upgrade potential; weaker capital markets remain the key risk.
Target price is $26.00 Current Price is $20.71 Difference: $5.29
If CHC meets the UBS target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $24.97, suggesting upside of 20.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 51.00 cents and EPS of 103.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 103.1, implying annual growth of 116.0%. Current consensus DPS estimate is 50.8, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 20.1. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 54.00 cents and EPS of 118.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 113.4, implying annual growth of 10.0%. Current consensus DPS estimate is 53.8, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 18.3. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CKF COLLINS FOODS LIMITED
Food, Beverages & Tobacco
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.99
Citi rates CKF as Neutral (3) -
Citi sees resilient Australian chicken demand as supportive for Collins Foods, but rising input costs could create greater-than-expected margin pressure.
Today, Inghams Group ((ING)) reported strong Australian quick-service restaurant chicken volumes despite consumer weakness, suggesting to the analyst the category continues to gain share.
However, the broker cautions rising feed, transport and packaging costs signal increasing cost of goods sold pressures, adding to existing labour and rent inflation.
Citi has opened a 30-day downside Catalyst Watch for Collins Foods ahead of the September AGM, anticipating a potentially weaker margin outlook.
Neutral rated. Target $8.80.
Target price is $8.80 Current Price is $8.00 Difference: $0.8
If CKF meets the Citi target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $9.30, suggesting upside of 16.3% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 52.3, implying annual growth of 39.8%. Current consensus DPS estimate is 30.8, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 15.3. |
Forecast for FY28:
Current consensus EPS estimate is 62.1, implying annual growth of 18.7%. Current consensus DPS estimate is 35.5, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 12.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CWY CLEANAWAY WASTE MANAGEMENT LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.60
Macquarie rates CWY as No Rating (-1) -
Cleanaway Waste Management reported FY26 results in line with guidance, with profit and the dividend both up 14%. Earnings guidance for FY27 is reiterated.
Macquarie is on research restriction.
Current Price is $2.63. Target price not assessed.
Current consensus price target is $2.91, suggesting upside of 10.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 8.00 cents and EPS of 12.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.6, implying annual growth of 163.6%. Current consensus DPS estimate is 7.8, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 22.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 9.50 cents and EPS of 14.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.4, implying annual growth of 15.5%. Current consensus DPS estimate is 8.9, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 19.6. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates CWY as Downgrade to Equal-weight from Overweight (3) -
Cleanaway's FY26 EBIT of $470m was at the midpoint of guidance, with improved returns and a strong contribution from Contract Resources helping offset weakness in Health and Industrial Services.
Morgan Stanley views FY27 as a transitional year, with growth from collections, a recovery in Health and further Contract Resources growth offset by higher IT and Blueprint 2.0 costs.
Management is targeting another $25m of indirect cost savings.
Following EQT Infrastructure's $3.13 per share proposal, the broker expects the stock to trade more on the potential transaction than fundamentals.
Morgan Stanley downgrades to Equal-weight from Overweight and raises the target to $3.10 from $2.91, reflecting the offer price less the 3.5c final dividend.
Industry View: In-Line.
Target price is $3.10 Current Price is $2.63 Difference: $0.47
If CWY meets the Morgan Stanley target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $2.91, suggesting upside of 10.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 7.30 cents and EPS of 10.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.6, implying annual growth of 163.6%. Current consensus DPS estimate is 7.8, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 22.7. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 8.20 cents and EPS of 12.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.4, implying annual growth of 15.5%. Current consensus DPS estimate is 8.9, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 19.6. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.68
UBS rates DOW as Neutral (3) -
On further inspection, UBS lowers the target to $7.20 from $8 and retains a Neutral rating. The analyst notes the shares fell -10% after the FY26 results, which is attributed to the higher-than-usual 2H earnings skew guidance, despite in-line FY27 guidance.
EPS forecasts are largely unchanged.
First Read: UBS notes Downer EDI's FY26 EBITA was in line with its forecast and consensus, as stronger margins offset weaker revenue.
Energy & Utilities outperformed expectations on energy transition activity and improved project execution, while Transport benefited from better execution and stabilisation in Australian Road Services, partly offset by weaker Facilities earnings.
FY27 guidance points to revenue, earnings and margin growth broadly consistent with forecasts, although the analyst highlights a larger than usual 2H weighting due to contract award timing and the ramp-up of secured work.
This implies mid-single-digit downgrades to 1H27 revenue and EBITA forecasts. The broker notes management remains confident in its FY30 ambitions for 4%-5% revenue CAGR and an EBITA margin approaching 6%.
Neutral. Target $8.
Target price is $7.20 Current Price is $6.59 Difference: $0.61
If DOW meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $8.32, suggesting upside of 26.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 32.00 cents and EPS of 46.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 47.1, implying annual growth of 44.6%. Current consensus DPS estimate is 31.8, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 33.00 cents and EPS of 49.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 49.0, implying annual growth of 4.0%. Current consensus DPS estimate is 33.0, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 13.4. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates DXS as Outperform (1) -
Dexus' FY26 funds from operations were flat year on year and in line with guidance. FY27 guidance of 37.5-39.5cps compares to consensus of 39.6cps and a dividend of 37.0cps compares to 34.6cps.
Office occupancy improved to 95.7%, industrial effective income was up 8.3%, and portfolio valuations 1.0%. However, FY27 earnings face a -12% to -17% step-down due to lower trading profits and performance fees, fund headwinds and higher finance costs, Macquarie notes.
Longer-term foundations are being established, but execution is key, the broker warns. Capital recycling creates capacity to recommence the buyback.
Target falls to $6.71 from $7.06 prior, Outperform retained.
Target price is $6.71 Current Price is $5.74 Difference: $0.97
If DXS meets the Macquarie target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $6.47, suggesting upside of 12.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 37.00 cents and EPS of 55.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 59.3, implying annual growth of 31.5%. Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 9.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 37.00 cents and EPS of 59.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.2, implying annual growth of 3.2%. Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 9.4. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates DXS as Neutral (3) -
On further inspection, the target price is raised to $6.38 from $6.12 with FY27/FY28 EPS forecasts tweaked slightly higher.
Dexus is viewed as an increasingly interesting proposition following FY27 guidance, supported by a -34% discount to NTA, rebased AFFO growth of around 10% over three years and plans to release more than $2bn of capital for redeployment.
Further clarity on the APAC matter is considered important, as potential fees and debt-funded remediation could temper the emerging FY27 earnings growth trajectory.
UBS retains a preference for Buy-rated GPT Group ((GPT)), but believes investor interest in Dexus could rise quickly if its earnings growth proves sustainable.
First Read: Dexus' FY26 result was broadly in line, but FY27 AFFO guidance implies a -14% y/y decline and is around -3% below consensus.
Office occupancy improved to 95.7% and industrial like-for-like income growth remained strong at 8.3%, although industrial occupancy eased to 94.6%.
The broker highlights uncertainty around the strategic review of the $7.3bn infrastructure platform, which is expected to make a materially lower earnings contribution in FY27, while redemption requests have increased at the Dexus Healthcare Property Fund.
Neutral. Target $6.12.
Target price is $6.38 Current Price is $5.74 Difference: $0.64
If DXS meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $6.47, suggesting upside of 12.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 37.00 cents and EPS of 57.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 59.3, implying annual growth of 31.5%. Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 9.7. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 39.00 cents and EPS of 63.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.2, implying annual growth of 3.2%. Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 9.4. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $16.54
Bell Potter rates EOL as Buy (1) -
Energy One's FY26 underlying EBITDA rose 28% and underlying NPAT increased 56%, both slightly below Bell Potter's and consensus forecasts.
ARR growth of 13% met revised guidance but was also below expectations. The analyst emphasises strong margin expansion, although higher customer churn and slowing European growth were areas of concern.
Management's FY27 recurring revenue growth is targeted at a minimum of 15%.
The proposed all-scrip acquisition of European energy software provider GMSL is viewed positively, with the transaction expected to be 35% EPS accretive on an FY26 pro forma basis and offer around $4.1m in potential EBITDA synergies.
FY27 and FY28 EPS forecasts are lowered by -7% and -9%, respectively, due to lower revenue and higher amortisation forecasts, while the target rises to $19.10 from $17.10. Buy rating retained.
Target price is $19.10 Current Price is $17.11 Difference: $1.99
If EOL meets the Bell Potter target it will return approximately 12% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 EPS of 42.90 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 22.00 cents and EPS of 55.50 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $17.95
Bell Potter rates FMG as Hold (3) -
Bell Potter describes Fortescue's FY26 result as mixed, with revenue and underlying EBITDA slightly ahead of forecasts and consensus, but underlying NPAT and the final dividend falling short.
Record iron ore shipments of 201.3Mt and a 7% increase in realised prices supported earnings, although C1 costs rose 4% amid higher energy prices and inflation.
The broker views the outlook as challenging, with FY27 guidance implying around 13% cost inflation, while subdued iron ore fundamentals, a stronger AUD and potential pricing pressure from Chinese buyer CMRG present further risks.
Bell Potter retains its Hold rating and lowers the target to $17.10 from $17.40.
Target price is $17.10 Current Price is $17.75 Difference: minus $0.65 (current price is over target).
If FMG meets the Bell Potter target it will return approximately minus 4% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $18.20, suggesting upside of 2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 60.00 cents and EPS of 77.24 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.6, implying annual growth of N/A. Current consensus DPS estimate is 71.7, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 65.00 cents and EPS of 103.47 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 127.6, implying annual growth of 3.2%. Current consensus DPS estimate is 81.7, implying a prospective dividend yield of 4.6%. Current consensus EPS estimate suggests the PER is 13.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates FMG as Underweight (5) -
Morgan Stanley views Fortescue's FY26 result as a modest miss, with underlying EBITDA of US$8.64bn -2% below both the broker and consensus and underlying NPAT missing by -5% and -4%, respectively, largely due to higher than expected Iron Bridge costs.
The final dividend of 46c brought FY26 dividends to $1.08 per share, also below expectations, while free cash flow of US$3.30bn was broadly in line.
The broker highlights the 153% increase in the Blacksmith Mineral Resource and maiden 196Mt Ore Reserve as positive, but expects higher costs and a sharp decline in Fortescue's dividend yield to around 3%-4% in FY27/28.
Morgan Stanley maintains its Underweight rating and $15.55 target.
Industry view: Attractive.
Target price is $15.55 Current Price is $17.75 Difference: minus $2.2 (current price is over target).
If FMG meets the Morgan Stanley target it will return approximately minus 12% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $18.20, suggesting upside of 2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 96.18 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.6, implying annual growth of N/A. Current consensus DPS estimate is 71.7, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 113.67 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 127.6, implying annual growth of 3.2%. Current consensus DPS estimate is 81.7, implying a prospective dividend yield of 4.6%. Current consensus EPS estimate suggests the PER is 13.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates FMG as Hold (3) -
Morgans maintains a Hold rating for Fortescue with its target price reduced to $18.70 from $21.80 following a mixed FY26 financial result where higher revenue offset cost pressures and elevated administration and R&D expenses.
Key figures included underlying EBITDA of US$8,635m on revenue of US$16,966m, delivering a 51% margin alongside an underlying NPAT of US$3,458m.
The analyst highlights ongoing operational and cost challenges at the Iron Bridge magnetite operation as a key issue, with ramp-up constraints requiring volume prioritisation over higher-margin hematite operations.
The broker's estimates reflect adjustments to medium and long-term operating cost assumptions, as well as a reduction in the forward EBITDA multiple applied in the blended valuation.
Target price is $18.70 Current Price is $17.75 Difference: $0.95
If FMG meets the Morgans target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $18.20, suggesting upside of 2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 83.36 cents and EPS of 170.65 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.6, implying annual growth of N/A. Current consensus DPS estimate is 71.7, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 74.47 cents and EPS of 122.71 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 127.6, implying annual growth of 3.2%. Current consensus DPS estimate is 81.7, implying a prospective dividend yield of 4.6%. Current consensus EPS estimate suggests the PER is 13.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates FMG as Accumulate (2) -
Ord Minnett maintains its Accumulate rating for Fortescue and cuts its target to $19.50 from $20.00 after FY26 underlying NPAT of US$3.5bn missed consensus by -6%.
Free cash flow of US$3.2bn was stronger than expected, but elevated spending on copper, renewable energy, fleet renewal and Blacksmith limits balance-sheet flexibility, commentary adds.
FY27-FY29 EPS forecasts fall -3.9%, -9.4% and -7.7%, respectively, reflecting higher costs and administration expenses.
Target price is $19.50 Current Price is $17.75 Difference: $1.75
If FMG meets the Ord Minnett target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $18.20, suggesting upside of 2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 78.00 cents and EPS of 174.88 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.6, implying annual growth of N/A. Current consensus DPS estimate is 71.7, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 62.00 cents and EPS of 135.53 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 127.6, implying annual growth of 3.2%. Current consensus DPS estimate is 81.7, implying a prospective dividend yield of 4.6%. Current consensus EPS estimate suggests the PER is 13.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates FMG as Neutral (3) -
UBS views Fortescue's FY26 result as mixed, with underlying EBITDA of US$8.6bn beating market expectations by 2%, but NPAT, EPS and the final dividend falling short as higher depreciation weighed on earnings conversion.
The broker highlights the 46c final dividend as a key disappointment, while rising FY27 capex and cost pressures could constrain shareholder returns, although the Blacksmith reserve upgrade provides some longer-term upside.
UBS raises FY27-FY28 EPS forecasts by 2%, but sees FY27 costs and higher capex as key earnings and free cash flow risks.
Neutral rating retained. Target lowered to $18.35 from $19.05.
Target price is $18.35 Current Price is $17.75 Difference: $0.6
If FMG meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $18.20, suggesting upside of 2.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 77.00 cents and EPS of 126.79 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.6, implying annual growth of N/A. Current consensus DPS estimate is 71.7, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 118.00 cents and EPS of 190.91 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 127.6, implying annual growth of 3.2%. Current consensus DPS estimate is 81.7, implying a prospective dividend yield of 4.6%. Current consensus EPS estimate suggests the PER is 13.9. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
Medical Equipment & Devices
More Research Tools In Stock Analysis - click HERE
Overnight Price: $35.74
Citi rates FPH as Neutral (3) -
First Take: Fisher & Paykel Healthcare upgraded FY27 revenue and NPAT guidance following stronger than expected performance from its hospital segment in 1H27.
Citi notes the new NZ$2.47bn-NZ$2.57bn revenue range is around 4% higher at the midpoint, although both the broker and consensus were already above the revised midpoint.
The analyst believes the 1H27 outlook is ahead of consensus and, with no obvious impediments in 2H27, expects the upgraded full-year guidance to be viewed as conservative.
Neutral. Target NZ$40.
Current Price is $36.31. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in March.
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 77.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 253.8, implying annual growth of N/A. Current consensus DPS estimate is 49.0, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 14.3. |
Forecast for FY28:
Citi forecasts a full year FY28 EPS of 89.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 88.6, implying annual growth of -65.1%. Current consensus DPS estimate is 55.4, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 41.0. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $8.01
Citi rates GMD as Buy (1) -
Genesis Minerals' FY26 results were broadly in line with Citi's expectations, with the maiden fully franked 5c dividend the key positive.
Revenue of $1.74bn met expectations, while underlying earnings (EBITDA) of $952m was broadly in line and underlying profit of $547m was -1% below the broker's forecast.
Operating cash flow (OCF) reached $935m and year-end net cash was $217m, reinforcing strong cash generation, the analysts point out.
In Citi's view, investor attention will now shift to completion of the Vault Minerals ((VAU)) merger and the combined strategic outlook.
Target $8.60. Buy.
Target price is $8.60 Current Price is $8.32 Difference: $0.28
If GMD meets the Citi target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $8.58, suggesting upside of 3.1% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 56.8, implying annual growth of 3.9%. Current consensus DPS estimate is 1.5, implying a prospective dividend yield of 0.2%. Current consensus EPS estimate suggests the PER is 14.6. |
Forecast for FY28:
Current consensus EPS estimate is 66.0, implying annual growth of 16.2%. Current consensus DPS estimate is 33.0, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates GMD as Buy (1) -
Genesis Minerals' FY26 financials were in line with expectations, having already disclosed core metrics at the quarterly update, alongside standalone FY27 guidance.
UBS notes the key announcement from the release is the maiden fully franked 5c dividend and that its previously announced merger with Vault Minerals ((VAU)) remains on track to complete in November.
Genesis confirmed its plans to release its new strategic plan in the second half FY27, though UBS understands work is already underway. UBS makes minimal earnings changes and remains Buy-rated. Target rises to $9.80 from $9.65.
Target price is $9.80 Current Price is $8.32 Difference: $1.48
If GMD meets the UBS target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $8.58, suggesting upside of 3.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 6.00 cents and EPS of 60.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.8, implying annual growth of 3.9%. Current consensus DPS estimate is 1.5, implying a prospective dividend yield of 0.2%. Current consensus EPS estimate suggests the PER is 14.6. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 33.00 cents and EPS of 66.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 66.0, implying annual growth of 16.2%. Current consensus DPS estimate is 33.0, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $28.78
Bell Potter rates GMG as Downgrade to Hold from Buy (3) -
Goodman Group's FY26 operating EPS of 129.9c increased 10% y/y and was in line with Bell Potter and consensus forecasts, while FY27 guidance for 9% growth is slightly below consensus.
The analyst points to a 37% increase in development WIP to $19.7bn, with data centres now representing 78% of the total, supporting higher development yields and production.
The recent 50MW hyperscaler lease in Japan is viewed as an important validation of Goodman's ability to secure customers across its 6.4GW power bank, although development and monetisation will take time.
FY27-FY29 EPS forecasts are slightly adjusted downwards while Bell Potter downgrades to Hold from Buy with a $32.65 target, viewing FY27 as another year of investment and building towards future returns.
Target price is $32.65 Current Price is $27.27 Difference: $5.38
If GMG meets the Bell Potter target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $34.59, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 30.00 cents and EPS of 140.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.9, implying annual growth of 5.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 19.1. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 30.00 cents and EPS of 154.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 156.8, implying annual growth of 9.7%. Current consensus DPS estimate is 30.3, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 17.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates GMG as Outperform (1) -
Goodman Group's FY26 operating earnings, up 10.1% on FY25, were marginally ahead of consensus. FY27 guidance for growth of 9% is marginally below consensus, Macquarie comments.
The combination of an additional four projects and an upgrade of projects from powered shell to fully fitted added $4.1bn to the work-in-progress in the June Q.
A global hyperscaler 20-year signed lease for first 50MW of Tsukuba Tech Central's 1GW campus builds on Goodman's momentum in Japan.
Macquarie believes Goodman can generate a three-year earnings CAGR of 10%. The shares are now trading at a -13.1% discount to long-run PE. Outperform and $35.40 target retained.
Target price is $35.40 Current Price is $27.27 Difference: $8.13
If GMG meets the Macquarie target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $34.59, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 30.00 cents and EPS of 143.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.9, implying annual growth of 5.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 19.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 30.00 cents and EPS of 157.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 156.8, implying annual growth of 9.7%. Current consensus DPS estimate is 30.3, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 17.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates GMG as Hold (3) -
Ord Minnett maintains its Hold rating for Goodman Group and reduces its target to $28.25 from $29.50 because development completions are expected to be lower.
FY26 operating EPS grew 10% to $1.30 and Goodman guides to another 9% increase in FY27, supported by $19.7bn of work in progress, 78% of which relates to data centres.
Near-term EPS forecasts are largely unchanged. Ord Minnett argues slower data-centre commencements and growth already reflected in the valuation limit upside.
Target price is $28.25 Current Price is $27.27 Difference: $0.98
If GMG meets the Ord Minnett target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $34.59, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 30.00 cents and EPS of 143.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.9, implying annual growth of 5.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 19.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 30.00 cents and EPS of 157.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 156.8, implying annual growth of 9.7%. Current consensus DPS estimate is 30.3, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 17.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates GMG as Buy (1) -
Following on from yesterday's first take on Goodman Group's result, UBS notes that despite making solid progress on data centre partnering, JVs and leasing over the last 6-9 months, Goodman's total return is only 1% versus the A-REIT 200 and -13% versus the ASX200 year to date.
There is some frustration at the pace of announced progress to date. New disclosures show Goodman is getting to the pointy end for some assets with several unleased projects approaching delivery in 2027, UBS notes.
Pleasingly, customer demand remains incredibly strong, underpinning Goodman's decision to deliver more fully-fitted facilities and to operate assets across the world.
Target falls to $33.66 from $34.09, Buy retained.
Target price is $33.66 Current Price is $27.27 Difference: $6.39
If GMG meets the UBS target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $34.59, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 30.00 cents and EPS of 143.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.9, implying annual growth of 5.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 19.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 31.00 cents and EPS of 159.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 156.8, implying annual growth of 9.7%. Current consensus DPS estimate is 30.3, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 17.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GQG GQG PARTNERS INC
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.49
UBS rates GQG as Buy (1) -
First take: GQG Partners' H1 distributable earnings of US$234.9m modestly exceeded forecasts and the US3.62c dividend was around 3% ahead, assisted by a lower tax rate.
UBS notes fee margins remained resilient and costs were controlled, but the analyst believes consensus underestimates H2 outflows, particularly following weak August performance and the group's technology underweight.
Buy rating is retained, with improved investment performance the key catalyst and sustained outflows or key-person risk the main concerns.
Target drops slightly to $1.90.
Target price is $1.90 Current Price is $1.43 Difference: $0.475
If GQG meets the UBS target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $1.79, suggesting upside of 25.3% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 18.95 cents and EPS of 21.86 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.8, implying annual growth of N/A. Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 12.9%. Current consensus EPS estimate suggests the PER is 6.9. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 16.03 cents and EPS of 17.49 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.3, implying annual growth of -12.0%. Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 11.5%. Current consensus EPS estimate suggests the PER is 7.8. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
GYG GUZMAN Y GOMEZ LIMITED
Food, Beverages & Tobacco
More Research Tools In Stock Analysis - click HERE
Overnight Price: $23.97
Citi rates GYG as Sell (5) -
First Take: From Guzman y Gomez's FY26 results, Citi assesses healthy Australian trading and a much larger-than-expected dividend offset by slower restaurant rollout guidance.
Australian earnings (EBITDA) of $85m met guidance, while comparable sales rose 5.3%, driven by transaction volumes rather than pricing, the analysts explain.
FY27 comparable sales for the first seven weeks are tracking at high-single-digit growth, ahead of management's full-year expectation for mid-single-digit comp growth, Citi highlights.
Management expects the earnings margin to rise to between 6.7%-6.9% from 6.2%.
The broker notes FY27 guidance for 35 new Australian restaurants remains below the medium-term pace of around 40.
The board declared a 40.6c final dividend, including a 14.4c special dividend, well ahead of the 7c consensus forecast.
Sell rating. Target $18.35
Target price is $18.35 Current Price is $26.70 Difference: minus $8.35 (current price is over target).
If GYG meets the Citi target it will return approximately minus 31% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $26.15, suggesting downside of -2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 15.00 cents and EPS of 21.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.0, implying annual growth of 54.3%. Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 121.4. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 28.60 cents and EPS of 44.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 45.7, implying annual growth of 107.7%. Current consensus DPS estimate is 27.8, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 58.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates GYG as Neutral (3) -
First take: Guzman y Gomez's FY26 network sales increased 17.9% to $1.378bn and Australian underlying EBITDA rose 28.7% to $85m, while early FY27 comparable sales were running at high-single-digit growth.
Management guides to 35 new restaurants and a 6.7%-6.9% EBITDA margin, while the US exit supports a 14.4c special dividend and an expanded $100m buyback.
UBS retains Neutral, viewing strong domestic execution as offset by rollout risk and a demanding valuation. Target $28.
Target price is $28.00 Current Price is $26.70 Difference: $1.3
If GYG meets the UBS target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $26.15, suggesting downside of -2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 11.00 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.0, implying annual growth of 54.3%. Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 121.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 35.00 cents and EPS of 46.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 45.7, implying annual growth of 107.7%. Current consensus DPS estimate is 27.8, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 58.4. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.77
Ord Minnett rates HMY as Buy (1) -
Ord Minnett maintains Harmoney on Buy and lowers its target to $1.42 from $1.48 because of a higher assumed cost of capital.
FY26 cash NPAT of $13.5m exceeded guidance, while management targets more than $16m in FY27. Return on equity has risen to 23.1%.
Forecasts reflect continued loan-book growth and operating efficiencies. The report stipulates credit performance and funding conditions remain the main risks, with improved returns and potential sector consolidation providing catalysts.
Target price is $1.42 Current Price is $0.80 Difference: $0.62
If HMY meets the Ord Minnett target it will return approximately 77% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.50 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 0.00 cents and EPS of 14.30 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.22
Morgan Stanley rates HSN as Downgrade to Underweight from Overweight (5) -
Morgan Stanley views Hansen Technologies as a well-run and profitable software business, but sees FY27 as a transitional year as the company invests around -$10m more in AI and product development.
Revenue is expected to remain broadly flat and the EBITDA margin to fall to around 26% from 31%, prompting the broker to cut FY27-FY29 EBITDA forecasts by -13%–20% and EPS by -9%-16%, respectively.
While the AI investment is considered strategically sensible and the near-net-cash balance sheet provides capacity for bolt-on acquisitions, Morgan Stanley does not expect to know whether the spending can meaningfully lift growth until FY28-FY29.
With better risk/reward seen elsewhere in Australian software, the broker downgrades to Underweight from Overweight.
Target is cut to $3.20 from $6. Industry view is Attractive.
Target price is $3.20 Current Price is $3.26 Difference: minus $0.06 (current price is over target).
If HSN meets the Morgan Stanley target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $5.36, suggesting upside of 64.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 10.00 cents and EPS of 28.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.8, implying annual growth of 27.4%. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 10.9. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 10.00 cents and EPS of 30.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.3, implying annual growth of 5.0%. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 10.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates IPH as Neutral (3) -
IPH delivered modest FY26 profit growth, Macquarie notes, despite weak activity and FX headwinds impacting revenue growth and profitability. Highlights were the performance in Canada, corporate cost performance and capital management.
The A&NZ segment's underlying earnings were down -7.2% and it continues to be impacted by the decline in US Patent Cooperation Treaty (PCT) applications with IPH member firms disproportionately affected by their larger exposure to US clients relative to the market.
The corporate segment and capital management supported the overall result, Macquarie notes. Modest organic earnings growth and weak US PCT activity drag on the outlook.
Target falls to $3.65 from $3.74, Neutral retained.
Target price is $3.65 Current Price is $3.60 Difference: $0.05
If IPH meets the Macquarie target it will return approximately 1% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 37.50 cents and EPS of 45.70 cents. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 39.00 cents and EPS of 47.60 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates IPH as Buy (1) -
First take: IPH Ltd's FY26 is seen as broadly in line by Morgans with the broker noting both Canada and Asia showed topline growth, while A&NZ remains impacted by lower US PCT filings.
Buy rating retained on an undemanding valuation, though commentary suggests investors might still have to be patient. Target $4.65 (was $5.39).
With flat growth on the horizon, still, earnings forecasts have been reduced.
Target price is $4.65 Current Price is $3.60 Difference: $1.05
If IPH meets the Morgans target it will return approximately 29% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 39.00 cents and EPS of 47.00 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 40.00 cents and EPS of 49.00 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JHX JAMES HARDIE INDUSTRIES PLC
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $42.80
Citi rates JHX as Buy (1) -
First Take: Citi considers James Hardie's European divestment strategically sensible, strengthening the balance sheet and increasing its focus on Azek as the key long-term growth platform.
James Hardie is selling Fermacell to Holcim for EUR840m and closing its European Fibre Cement business, with the sale implying a healthy (in the broker's view) 12x trailing EBITDA multiple.
The transaction could dilute FY27 pro-forma EPS by mid-single digits, as lost European earnings outweigh interest savings and the benefit of a US$250m buyback, the analyst explains.
Citi also expects more than -US$100m of transaction-related cash costs.
Buy. Target price $42.60.
Target price is $42.60 Current Price is $42.84 Difference: minus $0.24 (current price is over target).
If JHX meets the Citi target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $45.62, suggesting upside of 6.5% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 184.6, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 23.2. |
Forecast for FY28:
Citi forecasts a full year FY28 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.6, implying annual growth of 20.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 19.3. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates JHX as Outperform (1) -
This morning, James Hardie Industries has announced the sale of its Fermacell business to Holcim and the closure of its fibre cement operations in Europe. The group will buy back $250m in stock as a consequence.
Macquarie, in a quick response, reminds investors James Hardie originally purchased Fermacell for EUR473m in 2018. Its own valuation of the European business sits at USD952m.
Macquarie thus concludes the valuation is solid, notwithstanding the net proceeds seemingly being around USD850m post the fibre cement exit.
Macquarie considers both today's disposal and capital reallocation a positive surprise. Outperform. Target $47.10.
Target price is $47.10 Current Price is $42.84 Difference: $4.26
If JHX meets the Macquarie target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $45.62, suggesting upside of 6.5% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 186.54 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 184.6, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 23.2. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 239.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 221.6, implying annual growth of 20.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 19.3. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
LIC LIFESTYLE COMMUNITIES LIMITED
Infra & Property Developers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $5.34
Citi rates LIC as Neutral (3) -
First Take: Citi assesses a mixed FY26 result for Lifestyle Communities, with weaker profit offset by solid settlements, positive development cash flow and a significantly improved balance sheet.
Operating profit of $25.4m missed consensus by -11%, primarily due to lower fair value uplifts, the analyst explains.
Lot settlements of 240 met consensus, while development generated $90.7m of cash inflows and margins reached 10.4%. While the development margin slightly exceeded guidance, it remains depressed compared to pre-VCAT levels of circa 21%, the analyst notes.
Net debt fell to $274m from $460m and the loan-to-value ratio improved to 28.7% from 47.8%.
The broker expects near-term share price weakness, with attention on the VCAT appeal relating to deferred management fees and a margin recovery.
Neutral rating. Target $5.80.
Target price is $5.80 Current Price is $5.50 Difference: $0.3
If LIC meets the Citi target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $5.59, suggesting upside of 1.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 24.6. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 5.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.4, implying annual growth of 13.4%. Current consensus DPS estimate is 4.1, implying a prospective dividend yield of 0.7%. Current consensus EPS estimate suggests the PER is 21.7. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates LIC as Neutral (3) -
First take: Lifestyle Communities' FY26 operating earnings fell -44% to $25.4m, matching UBS but missing consensus by -11%, while settlements declined to 240.
Fourth-quarter sales improved, but only 21 sales had been achieved early in FY27 and management provided no full-year guidance; completed unsold homes also increased to 120.
Neutral is retained, with lower gearing and improved gross development margins offset by subdued demand, inventory risk and limited earnings visibility. Target $5.70.
Target price is $5.70 Current Price is $5.50 Difference: $0.2
If LIC meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $5.59, suggesting upside of 1.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 20.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 24.6. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 4.00 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.4, implying annual growth of 13.4%. Current consensus DPS estimate is 4.1, implying a prospective dividend yield of 0.7%. Current consensus EPS estimate suggests the PER is 21.7. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MAF MA FINANCIAL GROUP LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.10
Morgans rates MAF as Buy (1) -
Morgans maintains a Buy rating for MA Financial with its target price increased marginally to $8.66 from $8.56 following a strong 1H26 underlying NPAT result of $35.9m, which grew 59% on the prior corresponding period and tracked in line with consensus expectations.
Underlying revenue reached $214m and underlying EBITDA hit $68m, both beating consensus by 1%-1.5% while achieving an underlying EBITDA margin expansion to 31.8%.
Positive post-balance-date commentary highlighted $166m of net inflows in the first six weeks of the second half, an MA Money loan book surpassing $8bn, and a robust rebound in Corporate Advisory deal flow.
Trading at approximately 13.5x FY27 earnings while offering robust multi-year growth potential, the stock is viewed as attractively priced by the broker.
Target price is $8.66 Current Price is $6.84 Difference: $1.82
If MAF meets the Morgans target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $9.30, suggesting upside of 36.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 25.80 cents and EPS of 51.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 651.6%. Current consensus DPS estimate is 25.5, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 14.6. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 26.90 cents and EPS of 53.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.3, implying annual growth of 20.0%. Current consensus DPS estimate is 30.6, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 12.1. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates MAF as Buy (1) -
Ord Minnett maintains its Buy rating for MA Financial and raises its target to $9.15 from $8.90 following an in-line first-half result and stronger-than-expected medium-term targets.
Underlying EBITDA of $68.2m was 1% ahead of consensus, while MA Money's contribution almost quadrupled and second-half asset-management flows have improved.
FY26-FY28 EBITDA forecasts rise 1%-5%.
Target price is $9.15 Current Price is $6.84 Difference: $2.31
If MAF meets the Ord Minnett target it will return approximately 34% (excluding dividends, fees and charges).
Current consensus price target is $9.30, suggesting upside of 36.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 25.80 cents and EPS of 43.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 651.6%. Current consensus DPS estimate is 25.5, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 14.6. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 29.90 cents and EPS of 53.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.3, implying annual growth of 20.0%. Current consensus DPS estimate is 30.6, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 12.1. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MAF as Buy (1) -
Following on from yesterday's first read on the first half result, UBS notes MA Financial delivered an in-line result, though the broker thinks the share price reaction (up 18%) reflects material potential for upside towards new FY29 targets, and a stronger second half outlook.
UBS continues to view MA Financial's valuation as attractive given improving earnings quality, with rising recurring revenues and operating leverage, a rising return on equity, and 12-month forward PE at a -15% discount to the three-year average.
Target rises to $10.10 from $9.30, Buy retained.
Target price is $10.10 Current Price is $6.84 Difference: $3.26
If MAF meets the UBS target it will return approximately 48% (excluding dividends, fees and charges).
Current consensus price target is $9.30, suggesting upside of 36.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 25.00 cents and EPS of 46.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 651.6%. Current consensus DPS estimate is 25.5, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 14.6. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 35.00 cents and EPS of 62.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.3, implying annual growth of 20.0%. Current consensus DPS estimate is 30.6, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 12.1. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MGH MAAS GROUP HOLDINGS LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $6.17
Macquarie rates MGH as Outperform (1) -
Maas Group's FY26 continuing operations EBITDA of $143m exceeded guidance of $130m-$135m, with Macquarie expecting strong revenue and profit growth in FY27 despite a softer than expected Construction and Hire result.
The broker highlights record electrical work in hand of around $1.2bn, progress on the Firmus contracts and around $1.3bn of expected proceeds from the Heidelberg transaction as key supports for the outlook.
Significant cash inflows through FY27-FY28 provide scope for M&A and capital returns, including a potential buyback of up to 20% of issued capital.
FY27-FY29 EPS forecasts tweaked by -7%, 2% and -6%, respectively. The company is viewed as being in a transition phase with the acceleration in growth in electrical business and Construction and Hire segments.
Outperform retained. Target rises 7% to $6.75.
Target price is $6.75 Current Price is $5.82 Difference: $0.93
If MGH meets the Macquarie target it will return approximately 16% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 13.40 cents and EPS of 32.10 cents. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 18.20 cents and EPS of 44.70 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates MGH as Buy (1) -
Morgans maintains a Buy rating for Maas Group with its target price increased to $7.75 from $7.30 following an FY26 financial result that landed in line with updated guidance.
Group underlying EBITDA reached $300.3m, representing a 37% increase on the prior corresponding period, while underlying NPAT rose 57% to $123.4m, and statutory NPAT surged 89% to $136.1m.
The broker's estimates suggest the electrical pivot is the primary focus, with the division formally known as Civil, Construction and Hire successfully transitioning to become an electrical contractor, securing an $855m Firmus purchase order.
Trading on strong growth forecasts, the stock is viewed as an attractive opportunity supported by a solid operating result and substantial fair value gains.
Target price is $7.75 Current Price is $5.82 Difference: $1.93
If MGH meets the Morgans target it will return approximately 33% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 43.30 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of 48.80 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.82
Morgans rates MLG as Speculative Buy (1) -
Morgans maintains a Speculative Buy rating for MLG Oz with its target price unchanged at $1.20 following an FY26 financial result that surpassed expectations across all key earnings metrics.
Revenue grew 4% year-on-year to $561.4m while underlying EBITDA rose 14% to $75.5m and NPAT jumped 34% to $14.5m, reflecting a refreshed strategic focus on prioritising profitability over top-line growth.
Second-half EBITDA margins expanded to 14.1%, approaching management's 15% target and representing the strongest margin performance in recent history.
The broker's estimates reflect minor top-line reductions offset by stronger operational margins, alongside a non-cash loss on sales assumption introduced across the forecast period.
Backed by an optimised haulage portfolio and an expanding civil order book, Morgans concludes the stock offers solid structural growth and compelling upside potential.
Target price is $1.20 Current Price is $0.80 Difference: $0.4
If MLG meets the Morgans target it will return approximately 50% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 2.50 cents and EPS of 11.00 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 3.00 cents and EPS of 12.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $19.31
Citi rates MP1 as Buy (1) -
Following Citi's initial research on Megaport's FY26 result, the analysts fielded investor queries on the weaker-than-expected share price on the day.
The broker attributes this weakness to funding uncertainty and procurement concerns. The procurement issue appears hardware-specific, although it raises questions around Megaport's position in the value chain, the analysts explain.
Capex guidance indicates confidence in securing required equipment, while Citi expects limited drawings from the new debt facility by end-FY27.
Buy rating and $22.10 target.
First Take: Lower operating costs drove Megaport's FY26 beat, with underlying EBITDA excluding share-based compensation rising 24% and coming in 8% ahead of Citi and consensus, while the 25% EBITDA margin exceeded the broker's 23% forecast.
Citi highlights accelerating Network ARR growth, improving NRR and further Latitude contract wins worth US$92m in ARR, while a new $825m debt facility fully funds committed capex.
FY27 guidance is also stronger than expected, with midpoint EBITDA 9% above consensus, although capex is 44% higher and equipment supply constraints have delayed compute procurement for two contracts.
The analyst expects a positive share price reaction.
Target price is $22.10 Current Price is $18.38 Difference: $3.72
If MP1 meets the Citi target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $23.30, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 8.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 218.8. |
Forecast for FY28:
Current consensus EPS estimate is 42.0, implying annual growth of 400.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 43.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates MP1 as Upgrade to Overweight from Equal-weight (1) -
Morgan Stanley notes Megaport's FY26 revenue rose 13%, in line with expectations, while EBITDA increased 24% for a small beat.
FY27 revenue guidance of $620-$730m compares with consensus of $620m, while EBITDA margin guidance of 38%-40% is broadly in line.
The contract computing business signed three new contracts worth $506m in total contract value and $129m in ARR, requiring -$292m of additional chip capex which management expects to fund internally.
The broker believes consensus materially underestimates the strength and duration of demand for CPUs/GPUs, computing, cloud and connectivity.
This provides a favourable backdrop across all three of Megaport's businesses and drives the upgrade to Overweight from Equal-weight.
Target price is raised to $25 from $12. Industry View: Attractive.
Target price is $25.00 Current Price is $18.38 Difference: $6.62
If MP1 meets the Morgan Stanley target it will return approximately 36% (excluding dividends, fees and charges).
Current consensus price target is $23.30, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 12.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 8.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 218.8. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 0.00 cents and EPS of minus 7.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 42.0, implying annual growth of 400.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 43.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MP1 as Buy (1) -
Following on from yesterday's first read of Megaport's FY26 result, UBS suggests there's lots to digest, creating some questions and confusion; however, the net outcome is firmly in the positive.
UBS rolls forward valuations, incorporating FY27 guidance, together with second-half KPIs and the new strategic contract developments.
The net impact increases FY27-FY30 earnings forecasts with upside should Megaport deliver stronger acceleration of annual recurring revenue or moderate cost reinvestment.
Target rises to $26.40 from $24.20, Buy retained.
Target price is $26.40 Current Price is $18.38 Difference: $8.02
If MP1 meets the UBS target it will return approximately 44% (excluding dividends, fees and charges).
Current consensus price target is $23.30, suggesting upside of 26.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 8.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 218.8. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 0.00 cents and EPS of 91.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 42.0, implying annual growth of 400.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 43.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.71
Citi rates MPL as Neutral (3) -
Following Medibank Private's FY26 results, Citi trims its target by -10c to $5.00.
Management expects policyholder growth to accelerate from 1.1% in FY26, although the 4Q performance raises some uncertainty around the FY27 outlook, the broker suggests. Hence, a Neutral rating is maintained.
First Take: In an initial review of Medibank Private's FY26 results, Citi assesses an in-line outcome and a higher-than-expected dividend. However, underwhelming private health insurance (PHI) growth and a lower Medibank Health gross margin are also noted.
Underlying profit of $637m was in line with consensus of $638m, note the analysts, and 10.9cps fully franked dividend is slightly ahead of consensus.
Softer-than-expected PHI revenue is the main cause of the slight miss to consensus on operating profit with net margins in line, the broker explains.
The analyst would not be surprised to see the stock price trade flat or slightly down today.
Target price is $5.00 Current Price is $4.95 Difference: $0.05
If MPL meets the Citi target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $5.15, suggesting upside of 4.1% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 25.5, implying annual growth of 10.0%. Current consensus DPS estimate is 20.4, implying a prospective dividend yield of 4.1%. Current consensus EPS estimate suggests the PER is 19.4. |
Forecast for FY28:
Current consensus EPS estimate is 26.5, implying annual growth of 3.9%. Current consensus DPS estimate is 21.0, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 18.7. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates MPL as Buy (1) -
Ord Minnett maintains Medibank Private on Buy and its $5.10 target after FY26 underlying NPAT increased 3% to $637m and broadly matched expectations.
Policyholder growth slowed in the second half, but claims inflation of 2.6% remained benign and should be covered by the recent 5.1% premium increase, commentary suggests.
FY27-FY29 EPS forecasts fall -1.5% to -2.0% annually because of lower membership growth and higher cyber-litigation costs.
Target price is $5.10 Current Price is $4.95 Difference: $0.15
If MPL meets the Ord Minnett target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $5.15, suggesting upside of 4.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 20.00 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of 10.0%. Current consensus DPS estimate is 20.4, implying a prospective dividend yield of 4.1%. Current consensus EPS estimate suggests the PER is 19.4. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 21.00 cents and EPS of 26.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.5, implying annual growth of 3.9%. Current consensus DPS estimate is 21.0, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 18.7. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MPL as Neutral (3) -
Following on from yesterday's first read on Medibank Private's FY26, UBS notes that while the result was in line, with Health Insurance margins having likely topped-out as government scrutiny of hospital benefit ratios persists, incrementally slower top-line drivers are increasingly in focus.
Medibank's FY27 outlook for stable private health insurance margins and market share gains appears increasingly incongruous given a rising need to reinvest for growth, UBS suggests.
As a result, while yesterday's -6% share price fall appears overplayed, leaving improved value headroom, with margin and volume outcome risks skewed more to the downside, UBS retains a Neutral rating. Target falls to $5.00 from $5.15.
Target price is $5.00 Current Price is $4.95 Difference: $0.05
If MPL meets the UBS target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $5.15, suggesting upside of 4.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 20.00 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of 10.0%. Current consensus DPS estimate is 20.4, implying a prospective dividend yield of 4.1%. Current consensus EPS estimate suggests the PER is 19.4. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 21.00 cents and EPS of 27.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 26.5, implying annual growth of 3.9%. Current consensus DPS estimate is 21.0, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 18.7. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Bell Potter rates NOU as Hold (3) -
A stronger than expected contribution from Dairy & Nutritionals helped Noumi achieve FY26 underlying EBITDA of $61.8m, broadly matching Bell Potter's forecast and recent guidance.
Dairy & Nutritionals EBITDA rose 95% to $21.6m, while Plant Based EBITDA fell -14% due to increased sales and marketing investment.
FY27 EBITDA forecast is trimmed by -1% and FY28 is lifted by 2%, with no formal FY27 guidance provided by the company.
The broker retains its Hold rating and $0.123 target, noting the share price remains capped by the current takeover offer.
Target price is $0.12 Current Price is $0.12 Difference: $0.003
If NOU meets the Bell Potter target it will return approximately 3% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.20 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 14.90 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NST NORTHERN STAR RESOURCES LIMITED
Gold & Silver
More Research Tools In Stock Analysis - click HERE
Overnight Price: $23.94
Macquarie rates NST as Neutral (3) -
On further inspection, the target price is lowered to $22.50.
After accounting for FY27 guidance, FY27 EPS forecasts are downgraded by -15% due to higher depreciation & amortisation. FY28-FY30 EPS forecasts are trimmed by -3% to -6% on higher cost assumptions.
Neutral rated.
First impressions: Northern Star Resources' FY26 result was broadly in line with expectations, with underlying NPAT beating consensus by 2% and the 55cps total dividend 5% ahead.
Macquarie views FY27 guidance as mixed, with gold sales of 1,575koz at the midpoint -3% below consensus and AISC of $3,250/oz 7% above, driven largely by higher costs at Yandal.
Growth capex guidance of $1.86bn was a positive, coming in -4% below consensus, while KCGM was the only operation to deliver sales guidance above expectations.
Neutral rating with a $23 target. Northern Star is expected to lag gold peers despite the stronger overnight gold price due to softer FY27 sales and cost guidance.
Target price is $22.50 Current Price is $23.97 Difference: minus $1.47 (current price is over target).
If NST meets the Macquarie target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $25.13, suggesting upside of 4.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 43.00 cents and EPS of 109.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 152.2, implying annual growth of 30.6%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 15.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 70.60 cents and EPS of 196.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 192.2, implying annual growth of 26.3%. Current consensus DPS estimate is 69.4, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 12.5. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates NST as Downgrade to Hold from Accumulate (3) -
Morgans moves its recommendation for Northern Star Resources to Hold from Accumulate with its target price increased marginally to $25.00 from $24.00 following an FY26 financial result that delivered underlying EBITDA of $4,271m and underlying NPAT of $1,790m alongside a better-than-expected final dividend of 30cps.
FY27 guidance met expectations at the headline level, though commissioning and ramp-up risks at KCGM remain key focal points for the second half of FY27 as the expanded plant targets improved performance.
Trading at an earnings discount to peers, the stock is viewed as fairly priced following recent share price strength, with the broker noting that the medium-term investment case remains supported by organic growth and cash flow expansion.
Target price is $25.00 Current Price is $23.97 Difference: $1.03
If NST meets the Morgans target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $25.13, suggesting upside of 4.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 59.00 cents and EPS of 184.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 152.2, implying annual growth of 30.6%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 15.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 91.00 cents and EPS of 290.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 192.2, implying annual growth of 26.3%. Current consensus DPS estimate is 69.4, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 12.5. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates NST as Hold (3) -
Ord Minnett maintains Northern Star Resources on Hold and lowers its target to $19.70 from $20.30 after softer FY27 production and cost guidance.
FY26 earnings were in line and the 30c final dividend exceeded the broker's estimate, but FY27 gold sales guidance was -3% below consensus and costs were 7% higher.
Forecasts were revised for the new guidance. Ord Minnett lines up KCGM ramp-up and leadership uncertainty as the main risks, while acquisitions or stronger delivery could unlock value.
Target price is $19.70 Current Price is $23.97 Difference: minus $4.27 (current price is over target).
If NST meets the Ord Minnett target it will return approximately minus 18% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $25.13, suggesting upside of 4.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 55.00 cents and EPS of 127.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 152.2, implying annual growth of 30.6%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 15.7. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 46.00 cents and EPS of 116.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 192.2, implying annual growth of 26.3%. Current consensus DPS estimate is 69.4, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 12.5. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates NST as Buy (1) -
Having guided earlier to $2,860-2,950m FY26 cash earnings, Northern Star Resources reported underlying FY26 earnings of $4,271m for -$628m free cash flow, finishing the year $0.38bn net cash.
The 30cps final dividend brought the FY26 to 55cps and at 27% of cash earnings, slightly ahead of expectations.
However, FY27 guidance did little to build confidence in the 3-5 year outlook and UBS waits for the arrival of the new CEO in October before multi-year guidance sometime next year.
Target rises to $24.25 from $24.05. Downgrade to Neutral from Buy.
Target price is $24.25 Current Price is $23.97 Difference: $0.28
If NST meets the UBS target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $25.13, suggesting upside of 4.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 49.00 cents and EPS of 130.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 152.2, implying annual growth of 30.6%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 15.7. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 70.00 cents and EPS of 165.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 192.2, implying annual growth of 26.3%. Current consensus DPS estimate is 69.4, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 12.5. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NWH NRW HOLDINGS LIMITED
Mining Sector Contracting
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.59
Macquarie rates NWH as Outperform (1) -
Macquarie sees NRW Holdings' growth outlook strengthening, with the Fredon acquisition performing well and emerging as a key source of upside risk to FY27/FY28 consensus forecasts.
FY26 EBITA beat consensus by 3%, while FY27 guidance is around 5% above consensus at the midpoint, supported by strong momentum across Fredon, Mining and MET.
The broker highlights a record $29.1bn pipeline, including $11.1bn of actively tendered work, while Fredon is targeting 20% revenue growth and an exit EBITA margin of 6% in FY27.
FY27-FY29 EPS forecasts are lifted by 3%, 4% and 4%. Target rises 4% to $8.60. Outperform rated.
Target price is $8.60 Current Price is $8.20 Difference: $0.4
If NWH meets the Macquarie target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $8.31, suggesting upside of 1.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 30.00 cents and EPS of 43.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.4, implying annual growth of 32.9%. Current consensus DPS estimate is 26.3, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 31.00 cents and EPS of 46.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 5.6%. Current consensus DPS estimate is 27.3, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 17.5. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates NWH as Accumulate (2) -
Morgans maintains an Accumulate rating for NRW Holdings with its target price increased to $8.80 from $8.00 following a strong FY26 result where NPATA and EPSA increased 44%.
Management guided to FY27 EBITDA of $320m to $330m, supported by clear growth drivers across the Mining, EMIT, and Civil divisions.
Mining operations benefit from the South Walker Creek expansion, Meandu commencement, and latent fleet capacity, while EMIT captures rising data centre demand.
The broker's estimates reflect upward revisions of 4%-5% for FY27-FY28 EBITDA, alongside a 9%-11% lift in NPATA forecasts.
Target price is $8.80 Current Price is $8.20 Difference: $0.6
If NWH meets the Morgans target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $8.31, suggesting upside of 1.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 25.00 cents and EPS of 45.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.4, implying annual growth of 32.9%. Current consensus DPS estimate is 26.3, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 26.00 cents and EPS of 48.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 5.6%. Current consensus DPS estimate is 27.3, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 17.5. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates NWH as Buy (1) -
Following on from yesterday's first read on NRW Holdings' FY26, UBS suggests this was another solid set of results. One of the key questions for the company in FY27 is how it will manage its life post-Fimiston.
UBS thinks NRW is currently seeing an elevated bid-win rate compared to 6-12 months ago with the capacity of its major peers close to being full. This could see NRW not only replenish but grow its order book to smooth out its topline profile.
NRW has increased its senior banking facilities, effectively taking its available liquidity to $718m. This could be signalling that NRW could actively pursue M&A opportunities, UBS suggests.
Target rises to $8.50 from $7.95, Buy retained.
Target price is $8.50 Current Price is $8.20 Difference: $0.3
If NWH meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $8.31, suggesting upside of 1.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 24.00 cents and EPS of 44.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.4, implying annual growth of 32.9%. Current consensus DPS estimate is 26.3, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 25.00 cents and EPS of 46.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.9, implying annual growth of 5.6%. Current consensus DPS estimate is 27.3, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 17.5. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PPM PEPPER MONEY LIMITED
Business & Consumer Credit
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.81
Citi rates PPM as Buy (1) -
Citi considers Pepper Money's 1H26 result sound, supported by record loan originations, disciplined cost control and net interest margin (NIM) expansion.
Profit rose 15% year-on-year, while whole loan sales contributed 11% of income amid solid demand for Australian fixed-income instruments, the analyst explains.
New mortgage applications have fallen around -15% since May, and it is thought lower self-managed super fund lending could weigh on volumes.
Citi considers Pepper Money well positioned to manage cyclical volume changes given management's track record.
Buy rating. Target price $2.05.
Target price is $2.05 Current Price is $1.94 Difference: $0.11
If PPM meets the Citi target it will return approximately 6% (excluding dividends, fees and charges).
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PWH PWR HOLDINGS LIMITED
Automobiles & Components
More Research Tools In Stock Analysis - click HERE
Overnight Price: $10.52
UBS rates PWH as Neutral (3) -
PWR Holdings posted a small FY26 beat versus consensus, UBS notes, with FY27 commentary pointing to earnings upgrades across motorsports likely offsetting Aerospace & Defence (A&D) downgrades.
The FY27 statutory profit margin (including Poland) is to improve 2ppt versus 10.5% in FY26. FY27 revenue growth is expected to be driven by A&D. The A&D Poland manufacturing site will commence initial operations in FY27.
It was a solid FY26 result, UBS suggests, led by outperformance within motorsports, slightly softened by less than expected A&D revenues.
Into FY27, the key driver of earnings growth will be A&D with current growth trajectory of 30% expected to continue.
Neutral and $10 target retained.
Target price is $10.00 Current Price is $12.15 Difference: minus $2.15 (current price is over target).
If PWH meets the UBS target it will return approximately minus 18% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $10.13, suggesting downside of -16.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 12.00 cents and EPS of 24.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.8, implying annual growth of 28.2%. Current consensus DPS estimate is 11.8, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 53.3. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 17.00 cents and EPS of 34.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 34.0, implying annual growth of 49.1%. Current consensus DPS estimate is 17.0, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 35.7. |
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.34
Citi rates QAL as Buy (1) -
Returning from a conference call with management, Citi analysts are even more convinced that Qualitas' guidance for FY27 will prove conservative.
Conclusion: the business appears to be on strong footing, supported by a positive start to the year, while FY27 offers more earnings levers than were available in FY26.
Target $4.20. Buy. Citi believes management has missed an opportunity in not guiding to FY27 performance above consensus and therefore sees a compelling risk-reward on offer.
Target price is $4.20 Current Price is $3.22 Difference: $0.98
If QAL meets the Citi target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $3.95, suggesting upside of 22.7% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 17.1, implying annual growth of 20.8%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 18.8. |
Forecast for FY28:
Current consensus EPS estimate is 21.6, implying annual growth of 26.3%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates QAL as Outperform (1) -
Strong deployment momentum and expanding margins have Macquarie increasingly confident Qualitas can comfortably achieve its FY27 earnings guidance.
FY26 EPS of 14.7c was in line with consensus and 3% ahead of the broker's forecast, while Funds Management EBITDA margins expanded around 200bps to 54.3%.
The analyst sees further upside from 21% growth in fee-earning FUM, rising performance fees and continued operating leverage, with FY27 deployment also off to a strong start.
FY27-FY29 EPS forecasts are raised by 3.3%, 4.8% and 4.3%, respectively.
Outperform rating is reiterated. Target rises to $4.15 from $3.95.
Target price is $4.15 Current Price is $3.22 Difference: $0.93
If QAL meets the Macquarie target it will return approximately 29% (excluding dividends, fees and charges).
Current consensus price target is $3.95, suggesting upside of 22.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 14.80 cents and EPS of 17.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.1, implying annual growth of 20.8%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 18.8. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 16.90 cents and EPS of 21.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 21.6, implying annual growth of 26.3%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.59
Morgan Stanley rates RDX as Equal-weight (3) -
Morgan Stanley sees Redox entering FY27 with positive momentum after resilient FY26 organic volume growth and well-controlled costs, with delayed chemical price inflation now providing a tailwind into 1H27.
The broker highlights accelerating organic growth, 34% US growth and potential North American M&A, but remains cautious about forecasting earnings beyond FY27 given uncertainty around pricing and gross margin normalisation.
FY27 EPS are raised by 5% but FY28 forecasts are tweaked lower by -1%, noting the longer-term sustainable growth rate remains difficult to determine.
The broker remains Equal-weight on valuation with a $3.90 target, down from $4. Industry view: In-Line.
Target price is $3.90 Current Price is $3.29 Difference: $0.61
If RDX meets the Morgan Stanley target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $3.88, suggesting upside of 18.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 11.90 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.0, implying annual growth of 8.6%. Current consensus DPS estimate is 13.3, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 12.50 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.8, implying annual growth of 4.2%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 16.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates RDX as Accumulate (2) -
Ord Minnett maintains its Accumulate and raises its target for Redox to $3.75 from $3.30, up 13.6%, following a broadly in-line FY26 result.
Underlying NPAT increased 9% to $87m, while $123m of cash and no long-term debt provide capacity for acquisitions and organic investment.
Updated forecasts project EBITDA growth of 16% in FY27.
Target price is $3.75 Current Price is $3.29 Difference: $0.46
If RDX meets the Ord Minnett target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $3.88, suggesting upside of 18.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 13.00 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.0, implying annual growth of 8.6%. Current consensus DPS estimate is 13.3, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 14.00 cents and EPS of 20.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.8, implying annual growth of 4.2%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 16.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates RDX as Buy (1) -
UBS expects a favourable FY27 for Redox, supported by higher chemical prices and resilient volumes, although margins should moderate in 2H27.
Further re-rating is likely to require resilient volumes or accretive US acquisitions. Buy rated. Target slips to $4 from $4.20. EPS forecasts are tweaked lower.
First Read: Redox's FY26 result was broadly in line at the EBITDA and underlying NPAT level, with stronger-than-expected gross margins a key positive.
Revenue increased 7% y/y and EBITDA rose 10% y/y, while operating cash flow jumped 84%, supported by improved working capital, leaving the company with $77m net cash.
US organic revenue growth of 34% was also ahead of the broker's forecast, driven by new products and increased share of wallet.
Buy. Target $4.20.
Target price is $4.00 Current Price is $3.29 Difference: $0.71
If RDX meets the UBS target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $3.88, suggesting upside of 18.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 15.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.0, implying annual growth of 8.6%. Current consensus DPS estimate is 13.3, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 16.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.8, implying annual growth of 4.2%. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 16.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.90
UBS rates RIC as Buy (1) -
Upon further consideration, UBS maintains its FY27 EBITDA estimate of $190m. EPS forecasts fall -3% for FY27 and -2% for FY28 because of higher finance and corporate costs, before rising 1% in FY29.
Buy is retained, with acquisition synergies, cost savings and network optimisation offering upside, while fertiliser demand, integration and leverage are the major risks.
Target improves to $3.25 (up 5c).
First Read: Ridley Corp's FY26 EBITDA was 3% ahead of expectations, although higher finance costs associated with the Fertiliser acquisition and lease interest resulted in underlying NPAT broadly in line.
Fertiliser Distribution was the standout, with 2H26 EBITDA materially ahead of consensus, offset by softer Stockfeeds and Ingredients.
Operating cash flow was also ahead of expectations and net debt finished below the target range, supported by early Fertiliser sales.
Buy. Target $3.20.
Target price is $3.25 Current Price is $2.72 Difference: $0.53
If RIC meets the UBS target it will return approximately 19% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 12.00 cents and EPS of 20.00 cents. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 13.00 cents and EPS of 22.00 cents. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.26
Macquarie rates RSG as Outperform (1) -
Resolute Mining’s 1H26 NPAT of US$163m missed Macquarie and consensus forecasts by -19%, with higher operating costs and adverse fair value and treasury movements weighing on earnings.
Operating cash flow was viewed as the bright spot, beating the analyst's expectations by 19%. A robust net cash and bullion position of US$317m provides capacity to fund Doropo and absorb potential further disruption at Syama.
Management maintained 2026 production guidance of 250-275koz, although Macquarie and consensus are already forecasting below the range given Syama disruptions and the tight timeframe to ramp up the sulphide processing circuit.
2026/2027 EPS forecasts are tweaked down by -2%.
Outperform rated with an unchanged $1.45 target.
Target price is $1.45 Current Price is $1.34 Difference: $0.11
If RSG meets the Macquarie target it will return approximately 8% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 0.00 cents and EPS of 18.51 cents. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 17.20 cents. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $21.38
Bell Potter rates SHL as Buy (1) -
Sonic Healthcare's FY26 EBITDA of around $1.93bn was in line with consensus but around -1.5% below Bell Potter's forecast, with organic performance weighed down by the US and UK and Swiss regulatory changes.
The analyst highlights a meaningful improvement in 2H margins to around 19% from 16.7% in 1H, while the LADR acquisition contributed around $59m to NPAT and is achieving expected synergies.
FY27 EBITDA guidance implies around 6% constant currency growth.
FY27-FY29 EBITDA forecasts are downgraded by -3.7%, -5.1% and -5%, respectively, and assumes no margin improvement until sustained progress is evident.
Bell Potter retains its Buy rating and lowers the target to $27.50 from $28.75 following the earnings reductions and a higher WACC assumption.
Target price is $27.50 Current Price is $21.08 Difference: $6.42
If SHL meets the Bell Potter target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 110.00 cents and EPS of 126.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 112.00 cents and EPS of 133.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates SHL as Neutral (3) -
Sonic Healthcare's FY26 underlying EPS beat expectations by around 5%, but Citi highlights disappointing FY27 EBITDA guidance, which is around -4% below consensus at the midpoint and implies less than 5% constant currency growth.
The broker expects investors to remain cautious given unexpected Swiss fee cuts, wage pressures in A&NZ and the UK, investment in a multi-year digital transformation program and uncertainty around German reimbursement reform.
Citi lowers its FY27 forecasts but raises the target slightly on lower long-term capex assumptions.
The broker remains Neutral, believing the near-term negatives are reflected in the share price. Target $19.
Target price is $19.00 Current Price is $21.08 Difference: minus $2.08 (current price is over target).
If SHL meets the Citi target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 112.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
Citi forecasts a full year FY28 EPS of 132.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates SHL as Underweight (5) -
On a quick look at Sonic Healthcare's FY26, Morgan Stanley found the result largely in line with consensus. On a constant currency basis, FY26 earnings were largely in line with the broker's estimate.
FY27 earnings guidance sits -2% below consensus at the mid-point. This guidance excludes IT transformation costs of $30m, Morgan Stanley notes.
At the profit level, the mid-point of guidance sits 5% below. Underweight and $20.60 target retained for now. In-line industry view.
Target price is $20.60 Current Price is $21.08 Difference: minus $0.48 (current price is over target).
If SHL meets the Morgan Stanley target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 129.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 141.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates SHL as Downgrade to Hold from Buy (3) -
Morgans moves its recommendation for Sonic Healthcare to Hold from Buy with its target price decreased to $22.40 from $28.64.
The company reported FY26 underlying EBITDA of $1,933m, broadly aligning with expectations, and NPAT of $621m, which sat 4% ahead of consensus (excluding material NRIs).
Despite resilient 5% organic revenue growth, profitability was pressured by margin contraction in the US, UK, and Radiology divisions, offsetting gains elsewhere.
Looking forward, management's FY27 EBITDA guidance of $1.95bn to $2.03bn disappointed, hampered by multiple headwinds including Australian wage increases, a Swiss fee reduction, and integration costs.
The broker's estimates suggest these pressures will absorb much of the benefit derived from continued organic growth and expected US operational improvements, prompting a downward revision to forecast FY27-FY28 underlying earnings.
Target price is $22.40 Current Price is $21.08 Difference: $1.32
If SHL meets the Morgans target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 109.00 cents and EPS of 124.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 110.00 cents and EPS of 134.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates SHL as Hold (3) -
The title above the report says it all: Growth evaporates.
Ord Minnett maintains Sonic Healthcare on Hold with a revised target of $20.80 after FY27 guidance indicated little earnings growth despite FY26 revenue and EBITDA increasing 13% and 11%, respectively.
German synergies and US cost reductions are expected to be offset by reimbursement pressure, transformation expenses and higher depreciation and interest.
FY27-FY29 EPS forecasts fall -5.8%, -3.3% and -2.1%, respectively.
Target price is $20.80 Current Price is $21.08 Difference: minus $0.28 (current price is over target).
If SHL meets the Ord Minnett target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 110.00 cents and EPS of 123.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 113.00 cents and EPS of 138.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SHL as Neutral (3) -
Sonic Healthcare's FY26 underlying NPAT was 5% ahead of UBS's forecast, but the broker sees a much tougher outlook as funding cuts in Switzerland, higher UK wages and a stronger AUD weigh on earnings.
FY27 EBITDA guidance implies a broadly flat result before a further -$40m-$50m FX headwind at current rates, while restructuring of the US operations is expected to provide a $25m-$30m earnings benefit but does not address ongoing competitive pressures.
FY27/FY28 EPS forecasts fall by -7% and -14%, respectively, and the analyst sees further risk from potential funding cuts in Germany.
Neutral rated. Target rises to $21.20 from $19.60, largely due to lower capex assumptions.
Target price is $21.20 Current Price is $21.08 Difference: $0.12
If SHL meets the UBS target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $22.16, suggesting upside of 5.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 109.00 cents and EPS of 120.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 123.5, implying annual growth of 0.3%. Current consensus DPS estimate is 107.6, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 110.00 cents and EPS of 122.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 133.5, implying annual growth of 8.1%. Current consensus DPS estimate is 111.3, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.51
Macquarie rates SKC as Outperform (1) -
SkyCity reported NZ$182m FY26 uEBITDA, down -22% yoy, at the low end of the guidance but in line with expectations, Macquarie comments.
uEBITDA forecasts have been adjusted by -10% / +2% / +3% in FY27–FY29.
Macquarie sees dividends making a return in FY28 and has pencilled in NZ4c.
Leverage is due for decline as asset sales are in the pipeline, facilitating balance sheet repair.
Outperform. Target NZ59c.
Current Price is $0.50. Target price not assessed.
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.36 cents. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 3.40 cents and EPS of 4.67 cents. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.13
Morgans rates SLC as Hold (3) -
Morgans maintains its Hold rating for Superloop with its target price increased to $3.40 from $3.10 following an "impressive" FY26 result where underlying EBITDA of $122.7m beat consensus expectations by 2% and exceeded upgraded guidance.
Strong consumer subscriber growth pushed total subscriptions to 501k, achieving the three-year target, while business connectivity showed a welcome rebound in the second half.
The broker's estimates indicate that FY27 consensus expectations for roughly $150m of underlying EBITDA are comfortably achievable, underpinned by strong fixed-cost leverage and cash conversion.
Although the business boasts robust organic growth and a clean balance sheet, the stock is viewed as fairly priced after a strong share price run.
Target price is $3.40 Current Price is $3.06 Difference: $0.34
If SLC meets the Morgans target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $3.76, suggesting upside of 22.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.3, implying annual growth of 202.1%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 29.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 0.50 cents and EPS of 12.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.3, implying annual growth of 19.4%. Current consensus DPS estimate is 0.3, implying a prospective dividend yield of 0.1%. Current consensus EPS estimate suggests the PER is 24.9. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.82
Macquarie rates SPK as Outperform (1) -
Macquarie notes Spark New Zealand's FY26 adjusted EBITDAI of NZ$1,035m was within guidance, as mobile growth and cost-out partly offset legacy and Digital Services weakness.
As free cash flow (FCF) increased by 18.5% to NZ$308m, the company was able to pay out a rebased 16cps dividend and restore leverage to approximately 1.7x, commentary highlights.
It is Macquarie's view that FY27 guidance supports earnings stability, modest dividend growth and portfolio upside.
The suggestion is that investors should see Spark New Zealand as a self-help and portfolio simplification opportunity.
Outperform. Target NZ$2.73.
Current Price is $1.82. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 14.44 cents and EPS of 11.38 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.4, implying annual growth of N/A. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 7.8%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 14.19 cents and EPS of 12.66 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.9, implying annual growth of 13.2%. Current consensus DPS estimate is 16.6, implying a prospective dividend yield of 9.1%. Current consensus EPS estimate suggests the PER is 14.1. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SPK as Buy (1) -
UBS sees Spark's FY26 result as a step in the right direction, with EBITDA and free cash flow in line with guidance, while slowing mobile market share losses and lower than expected churn following price increases are encouraging.
FY27 free cash flow guidance implies 5.5% growth at the midpoint, while dividend guidance of NZD16-NZD18c is ahead of consensus.
The broker also sees upside from new mobile and wireless broadband products, a potential Digital Services sale and capital management.
EPS forecasts are downgraded by -15% for FY27 and -8% for FY28.
UBS maintains its Buy rating and NZ$3.00 target, with the more than 7% dividend yield providing valuation support.
Current Price is $1.82. Target price not assessed.
Current consensus price target is N/A
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 14.44 cents and EPS of 11.04 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.4, implying annual growth of N/A. Current consensus DPS estimate is 14.2, implying a prospective dividend yield of 7.8%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 19.54 cents and EPS of 13.59 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.9, implying annual growth of 13.2%. Current consensus DPS estimate is 16.6, implying a prospective dividend yield of 9.1%. Current consensus EPS estimate suggests the PER is 14.1. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SUL SUPER RETAIL GROUP LIMITED
Sports & Recreation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $14.45
Citi rates SUL as Buy (1) -
Citi raises its target for Buy-rated Super Retail by $2.00 to $16.20 following FY26 results.
First Take: In an early take, Citi remains positive on Super Retail after the release of today's FY26 earnings beat expectations, driven by a materially stronger second-half performance from Rebel.
The broker expects the earnings beat and solid trading update to drive a positive share price reaction, particularly following weakness ahead of the result.
FY26 normalised earnings (EBIT) of $389m beat consensus by around 7%, with Rebel benefiting from stronger sales and a 170bp gross margin improvement, the analyst explains.
Group sales rose 3.5% over the first eight weeks of FY27, while BCF is tracking ahead of Citi's expectations and currency movements should provide further tailwinds.
A 33cps final dividend also exceeded the broker's 24cps forecast.
Target price is $16.20 Current Price is $13.35 Difference: $2.85
If SUL meets the Citi target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $15.14, suggesting upside of 13.4% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 102.6, implying annual growth of 12.5%. Current consensus DPS estimate is 63.9, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY28:
Current consensus EPS estimate is 111.5, implying annual growth of 8.7%. Current consensus DPS estimate is 71.0, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates SUL as Underweight (5) -
Super Retail FY26 earnings came in 7.4% above consensus and profit 11.0% above, with Rebel the key driver and a lower effective tax rate also supporting profit.
Rebel was the clear positive, driving some 60% of the group earnings beat, with sales and gross profit margin benefiting from the World Cup and better promotional execution, Morgan Stanley notes.
The broker continues to see downside risk driven by pressure on consumer demand from higher rates, inflation and petrol prices, and elevated pricing and promotional intensity limiting margin recovery.
To turn more constructive on SCA and BCF, Morgan Stanley would need to see petrol prices moderate and a sustained pullback in market wide pricing and promotions, particularly in Auto, towards more rational levels.
Target rises to $11.90 from $11.20, Underperform retained. Industry view: Cautious.
Target price is $11.90 Current Price is $13.35 Difference: minus $1.45 (current price is over target).
If SUL meets the Morgan Stanley target it will return approximately minus 11% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $15.14, suggesting upside of 13.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 105.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 102.6, implying annual growth of 12.5%. Current consensus DPS estimate is 63.9, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 109.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 111.5, implying annual growth of 8.7%. Current consensus DPS estimate is 71.0, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates SUL as Hold (3) -
Morgans maintains a Hold rating for Super Retail with its target price increased to $15.20 following an FY26 sales result of $4,199.8m that delivered a better-than-expected underlying PBT of $306.2m, supported by Rebel World Cup tailwinds and resilient performance in Supercheap Auto.
Group LFL sales grew 1.9% in FY26, while trading through the first seven weeks of FY27 showed positive momentum in SCA and BCF, offsetting milder winter conditions impacting Macpac.
The broker's estimates reflect material EPS upgrades of 8%-13% across FY27-FY29, driven by improved group-wide margin expectations and valuation roll-forward.
Backed by a solid store rollout pipeline and a healthy net cash position, the valuation is viewed as reasonable relative to near-term growth expectations despite a challenging consumer discretionary backdrop.
Target price is $15.20 Current Price is $13.35 Difference: $1.85
If SUL meets the Morgans target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $15.14, suggesting upside of 13.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 67.00 cents and EPS of 102.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 102.6, implying annual growth of 12.5%. Current consensus DPS estimate is 63.9, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 73.00 cents and EPS of 113.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 111.5, implying annual growth of 8.7%. Current consensus DPS estimate is 71.0, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates SUL as Upgrade to Buy from Hold (1) -
Ord Minnett upgrades Super Retail to Buy from Hold and raises its target to $17.50 after FY26 NPAT of $226m beat consensus by 11%.
The broker believes Rebel's improved promotions, lower theft and 170-basis-point second-half gross-margin expansion mark the beginning of a broader turnaround, supported by resilient early FY27 trading.
FY27-FY29 EPS forecasts rise 9.6%, 7.8% and 7.5%, respectively.
Target price is $17.50 Current Price is $13.35 Difference: $4.15
If SUL meets the Ord Minnett target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $15.14, suggesting upside of 13.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 64.00 cents and EPS of 107.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 102.6, implying annual growth of 12.5%. Current consensus DPS estimate is 63.9, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 69.00 cents and EPS of 115.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 111.5, implying annual growth of 8.7%. Current consensus DPS estimate is 71.0, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SUL as Neutral (3) -
On further inspection, the target is raised to $14.25 from $12.35. FY27 EPS forecasts are lifted 5% and FY28 lowered slightly.
UBS retains its Neutral rating, recognising the strong positions of its four divisions across auto, sports and leisure markets, while remaining cautious on the consumer outlook and execution of the company's Investor Day strategy despite some early positive signs.
First Read: Super Retail Group's FY26 underlying PBT was 7% ahead of consensus and 4% above its forecast, driven particularly by stronger Rebel margins, alongside solid contributions from Supercheap Auto and BCF.
Early FY27 trading was mixed, with group like-for-like sales up 1.5% over the first seven weeks as strength in Supercheap Auto offset weakness in Macpac.
The broker considers overall trading better than feared, while FY27 guidance for group costs and capex is broadly in line with expectations.
Neutral. Target $14.25.
Target price is $14.25 Current Price is $13.35 Difference: $0.9
If SUL meets the UBS target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $15.14, suggesting upside of 13.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 66.00 cents and EPS of 100.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 102.6, implying annual growth of 12.5%. Current consensus DPS estimate is 63.9, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 71.00 cents and EPS of 109.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 111.5, implying annual growth of 8.7%. Current consensus DPS estimate is 71.0, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TCL TRANSURBAN GROUP LIMITED
Infrastructure & Utilities
More Research Tools In Stock Analysis - click HERE
Overnight Price: $13.96
Citi rates TCL as Neutral (3) -
Citi views Transurban's selection as part of the preferred consortium for Tennessee's US$9.2bn I-24 Choice Lanes project as a medium-term positive, adding to its US growth pipeline alongside the I-95 development framework.
However, the project represents a significant increase in medium-term capital commitments, with financial close expected in mid-2027.
Citi remains Neutral on Transurban, citing near-term free cash flow pressure and an unattractive valuation at around a 5.2% dividend yield.
Target price is $14.70 Current Price is $13.95 Difference: $0.75
If TCL meets the Citi target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $14.05, suggesting upside of 0.7% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 37.0, implying annual growth of 214.9%. Current consensus DPS estimate is 72.1, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 37.7. |
Forecast for FY28:
Current consensus EPS estimate is 40.5, implying annual growth of 9.5%. Current consensus DPS estimate is 74.9, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 34.4. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.20
Morgans rates TLC as Hold (3) -
Morgans maintains a Hold rating for Lottery Corp with its target price reduced to $5.60 from $5.70 following a resilient FY26 financial result delivered against an exceptionally weak 1 in 45-year jackpot cycle.
Group revenue declined -2.7% to $3,583m and underlying EBITDA fell -1.8% to $736m, with base game growth and strict operational cost control successfully offsetting significant jackpot headwinds.
The broker's estimates reflect cuts to top-line lotteries forecasts and lower earnings resulting from Keno revenue reclassification, the anticipated exit from online Keno, and higher interest costs associated with the Victorian licence renewal.
Trading on elevated valuation multiples, Morgans suggests the stock offers a defensive cash flow profile backed by exclusive long-duration licences.
Target price is $5.60 Current Price is $5.20 Difference: $0.4
If TLC meets the Morgans target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $5.78, suggesting upside of 11.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 17.00 cents and EPS of 16.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.9, implying annual growth of 32.1%. Current consensus DPS estimate is 18.5, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.8. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 18.00 cents and EPS of 17.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.8, implying annual growth of 5.3%. Current consensus DPS estimate is 19.7, implying a prospective dividend yield of 3.8%. Current consensus EPS estimate suggests the PER is 29.2. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $17.38
Bell Potter rates TLX as Buy (1) -
Bell Potter sees the pending FDA decision on Pixclara as the key near-term catalyst for Telix, expecting approval, albeit without high conviction, following extensive engagement with the regulator and submission of additional efficacy data.
Buy rated. Target unchanged at $19.
Flash Update: Telix Pharmaceuticals delivered a solid 1H26 result, with EBITDA of $52m modestly below Bell Potter's forecast but in line with consensus as higher R&D and marketing expenses weighed.
PSMA revenue was a highlight, rising 27%, while FY26 revenue and R&D spending guidance was maintained and excludes potential revenue from products awaiting regulatory approval.
Operating cash flow was $23m, including $40m received from Replimune, with closing cash of $251m, while underlying NPAT excluding the Replimune payment was broadly in line with the prior year.
Bell Potter notes the key near-term catalyst remains the FDA decision on Pixclara for brain cancer imaging.
Buy. Target $19.
Target price is $19.00 Current Price is $15.62 Difference: $3.38
If TLX meets the Bell Potter target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $26.23, suggesting upside of 67.9% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.52 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 211.1. |
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 40.22 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.0, implying annual growth of 224.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 65.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates TLX as Buy, High Risk (1) -
Citi sees Telix Pharmaceuticals entering a catalyst-rich period, with progress expected across Pixclara, Zircaix and TLX591 in the second half.
The broker has opened a 30-day upside Catalyst Watch, anticipating potential FDA approval for brain imaging agent Pixclara.
First-half results provided additional cost detail without major surprises, while FY26 guidance was unchanged, the analyst observes.
The broker's revenue forecast sits modestly above the US$950m-US$970m guidance range, implying around 29% growth for Precision Medicine.
The broker expects Zircaix resubmission within two months and sees potential near-term FDA approval for Pixclara.
Citi retains a Buy/High Risk rating. Target $31.
Target price is $31.00 Current Price is $15.62 Difference: $15.38
If TLX meets the Citi target it will return approximately 98% (excluding dividends, fees and charges).
Current consensus price target is $26.23, suggesting upside of 67.9% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.08 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 211.1. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.27 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.0, implying annual growth of 224.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 65.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates TLX as Overweight (1) -
Telix Pharmaceuticals had pre-reported 1H26 revenue and provided updated guidance as part of its June Q revenue result. Within Precision Medicine, 1H26 revenue implied market share gains, while gross margin showed improvement, with expansion ahead of Morgan Stanley's expectations.
The broker sees the current share price as implying a risked contribution from late-stage Precision Medicine candidates/indication expansion and no value from the Therapeutics portfolio.
As such, Morgan Stanley sees the risk-reward outlook as favourable at current levels. Overweight and $23.90 target retained. Industry View: In-Line.
Target price is $23.90 Current Price is $15.62 Difference: $8.28
If TLX meets the Morgan Stanley target it will return approximately 53% (excluding dividends, fees and charges).
Current consensus price target is $26.23, suggesting upside of 67.9% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Morgan Stanley forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.74 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.4, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 211.1. |
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.92 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.0, implying annual growth of 224.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 65.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.53
UBS rates TPG as Neutral (3) -
First take: TPG Telecom's H1 EBITDA increased 4% to $821m and underlying profit rose 9% to $70m, while the 10c dividend was 11% higher.
UBS notes mobile net additions of 65,000 fell short of guidance because of weaker wholesale volumes, and broadband subscribers declined by -42,000, although retail mobile trends improved.
The performance is seen as in line. Management has stuck with 2026 guidance.
UBS retains Neutral and leaves forecasts broadly unchanged, viewing cost control and the shift towards value brands as supportive but competition, regulation and capital expenditure as continuing risks. Target $3.97.
Target price is $3.97 Current Price is $3.81 Difference: $0.16
If TPG meets the UBS target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $3.87, suggesting upside of 1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 19.00 cents and EPS of 7.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 6.2, implying annual growth of -10.3%. Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 61.5. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 19.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 8.9, implying annual growth of 43.5%. Current consensus DPS estimate is 19.8, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 42.8. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.51
Bell Potter rates TPW as Downgrade to Hold from Buy (3) -
Temple & Webster's FY26 revenue of $665m-$675m was around -1% below Bell Potter and consensus forecasts, while EBITDA of $20m-$22m was around 4% ahead of consensus.
The broker highlights a weak start to FY27, with checkout revenue down -13% y/y over the first seven weeks, prompting the company to lower FY27 EBITDA guidance to $33m-$40m from its previous $40m target.
The analyst takes a cautious view on the pace of revenue recovery and cuts FY27-FY29 EBITDA forecasts by -15%, -25% and -8%, respectively.
The stock is downgraded to Hold from Buy. Target falls to $4.50 from $7, reflecting the earnings downgrades and ongoing risks around demand, competition and operating leverage.
Target price is $4.50 Current Price is $4.30 Difference: $0.2
If TPW meets the Bell Potter target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $5.15, suggesting upside of 19.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 10.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.2, implying annual growth of 209.4%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 38.4. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 9.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.8, implying annual growth of 14.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 33.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates TTX as Buy (1) -
Morgans maintains its Speculative Buy recommendation for Tetratherix with its target price unchanged at $8.59 following an FY26 result marked by initial licensing and grant revenue of $3.9m alongside a robust net cash position of $32.5m.
The period represented a transformational transition for the business into a commercial-stage biomaterials platform, highlighted by FDA submissions for Tegenix and TegenEOS, successful initial clinical progress for Tutelix, and a lucrative licensing agreement with Superpower Health.
The broker's estimates reflect minimal adjustments to forecasts, while numerous upcoming commercial catalysts in FY27 keep investor interest high.
Target price is $8.59 Current Price is $6.20 Difference: $2.39
If TTX meets the Morgans target it will return approximately 39% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 18.70 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 21.60 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UNI UNIVERSAL STORE HOLDINGS LIMITED
Apparel & Footwear
More Research Tools In Stock Analysis - click HERE
Overnight Price: $8.30
Bell Potter rates UNI as Buy (1) -
A stronger than expected FY26 result and solid early FY27 trading reinforce Bell Potter's positive view on Universal Store.
Group retail sales rose 9% y/y over the first seven weeks of FY27 despite challenging comparables, while guidance for 16-20 new stores was materially ahead of the broker's expectations.
FY27-FY29 NPAT forecasts are broadly unchanged as additional stores and improved gross margins are largely offset by higher wage costs and other investment.
Bell Potter retains its Buy rating and raises the target to $9.70 from $9.30.
Target price is $9.70 Current Price is $8.34 Difference: $1.36
If UNI meets the Bell Potter target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $10.47, suggesting upside of 25.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 41.20 cents and EPS of 54.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.4, implying annual growth of 137.4%. Current consensus DPS estimate is 40.4, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.8. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 46.60 cents and EPS of 61.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.6, implying annual growth of 11.0%. Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates UNI as Buy (1) -
Following FY26 results for Buy-rated Universal Store, Citi raises its target to $12.96 from $9.80, reflecting higher earnings, stronger retail peer multiples and a discounted cash flow (DCF) roll-forward.
The broker raises FY27 and FY28 EPS forecasts by 16% and 15%, respectively, reflecting higher sales and margins alongside lower net interest costs.
Longer-term assumptions are also lifted, with Perfect Stranger's store rollout now expected to reach 60 locations.
First Take: Universal Store's FY26 underlying NPAT was slightly ahead of consensus at $39.9m, while the 17cps final dividend beat 14.1cps consensus forecast.
Citi highlights the 140bps improvement in gross margin to 62.5%, while inventory declined despite double-digit revenue growth and 13 net store openings, and the group finished FY26 with $23.3m in net cash.
The key negative was further deterioration in the CTC wholesale business, which incurred another -$23.8m impairment and is considered potentially structurally challenged. Operating costs increased as a percentage of sales.
FY27 trading has started more slowly at Universal Store and THRILLS, although Perfect Stranger remains strong with like-for-like sales growth of 17.6%, the broker points out.
Target price is $12.96 Current Price is $8.34 Difference: $4.62
If UNI meets the Citi target it will return approximately 55% (excluding dividends, fees and charges).
Current consensus price target is $10.47, suggesting upside of 25.5% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 56.4, implying annual growth of 137.4%. Current consensus DPS estimate is 40.4, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.8. |
Forecast for FY28:
Current consensus EPS estimate is 62.6, implying annual growth of 11.0%. Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates UNI as Buy (1) -
Morgans maintains its Buy recommendation for Universal Store with its target price increased to $10.20 from $9.50.
Universal Store Holdings reported an impressive FY26 result featuring underlying EBIT growth of 17.2% to $64.0m, propelled by sales growth of 12.9%, a 140 basis point expansion in gross margin, and disciplined cost investment through a challenging retail environment.
The solid trading update highlighted an accelerating store rollout pipeline, with management guiding to 16 to 20 new store openings in FY27 following 13 new stores opened in FY26.
The broker's estimates show upward revisions of 0.7% and 2.7% to FY27 and FY28 EBITDA respectively, though higher depreciation costs temper EBIT growth by -3.0% and -2.0%.
Target price is $10.20 Current Price is $8.34 Difference: $1.86
If UNI meets the Morgans target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $10.47, suggesting upside of 25.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 26.90 cents and EPS of 53.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.4, implying annual growth of 137.4%. Current consensus DPS estimate is 40.4, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.8. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 32.20 cents and EPS of 64.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.6, implying annual growth of 11.0%. Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates UNI as Buy (1) -
UBS remains confident in Universal Store's revenue outlook, supported by strong merchandising and store execution, resilient spending amongst younger consumers and an accelerated rollout of 16-20 new stores in FY27.
The broker sees continued market share gains in the fragmented youth apparel market and raises its valuation multiple to reflect greater confidence in the outlook. EPS forecasts are tweaked lower by -5% for FY27 and -6% for FY28.
UBS retains its Buy rating and lifts the target to $9.25 from $9.00.
First Read: Universal Store's FY26 underlying EBIT was above consensus, in line with UBS' forecast and at the top end of guidance, led by strong Universal Store and Perfect Stranger performance.
Gross margin improved 140bps to 62.5%, while cash conversion remained strong and the group finished FY26 with $23.3m net cash.
Early FY27 trading is encouraging, with like-for-like sales up 2.9% at Universal Store and 17.6% at Perfect Stranger over the first seven weeks, despite tough comparables.
The analyst highlights strong momentum at Perfect Stranger and continued disciplined store expansion.
Buy rated. Target $9.
Target price is $9.25 Current Price is $8.34 Difference: $0.91
If UNI meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $10.47, suggesting upside of 25.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 43.00 cents and EPS of 56.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 56.4, implying annual growth of 137.4%. Current consensus DPS estimate is 40.4, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.8. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 48.00 cents and EPS of 62.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 62.6, implying annual growth of 11.0%. Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.61
Macquarie rates VCX as Neutral (3) -
On further inspection, the target is raised by 3% to $2.37 with FFO forecasts lifted across FY27-FY29 due to lower assumed net interest expenses.
Neutral rated with the higher valuation multiple ascribed reflecting the above-trend growth outlook, the analyst states.
First Impressions: Vicinity Centres' FY26 result was in line with expectations, with FFOps of 15.2cps and AFFOps of 13.0cps matching Macquarie and consensus.
FY27 guidance implies around 6% FFO growth and is broadly in line to slightly ahead of expectations, supported by 3.5% comparable NPI growth and a reduced development-related earnings drag.
The analyst highlights the completion of Chatswood Chase, which is expected to generate more than $250m in development profit, while further projects at Galleria and Uptown provide additional growth.
The broker also points to the strong balance sheet, positive property revaluations and 99.6% occupancy. Neutral with a $2.30 target.
Target price is $2.37 Current Price is $2.62 Difference: minus $0.25 (current price is over target).
If VCX meets the Macquarie target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.59, suggesting downside of -1.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 13.30 cents and EPS of 14.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of -48.0%. Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 13.70 cents and EPS of 14.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.3, implying annual growth of 3.8%. Current consensus DPS estimate is 13.9, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 16.1. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates VCX as Hold (3) -
Ord Minnett maintains its Hold rating for Vicinity Centres with a revised target of $2.55 after FY26 funds from operations increased 4.1% to 15.2c and reached the top of guidance.
Commentary posits FY27 growth should accelerate as Chadstone stabilises, Chatswood Chase contributes for a full year and Perth's Galleria reopens, supporting guidance of 16.0-16.2c.
FY27-FY29 forecasts rise 1.1%, 0.1% and 0.8%, respectively. The report concludes valuation is already around fair value and slower rental growth limits upside.
Target price is $2.55 Current Price is $2.62 Difference: minus $0.07 (current price is over target).
If VCX meets the Ord Minnett target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.59, suggesting downside of -1.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 14.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of -48.0%. Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 14.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.3, implying annual growth of 3.8%. Current consensus DPS estimate is 13.9, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 16.1. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates VCX as Downgrade to Neutral from Buy (3) -
Vicinity Centres' FY27 FFO guidance of 16.0-16.2c implies strong growth of 5.3%-6.6%, with comparable NOI growth accelerating to 4.2%, although UBS notes some softening in retail sales and re-leasing spreads amid a tougher consumer backdrop.
The broker highlights strong capital allocation, including improved expected development returns at Chatswood and Galleria and the sale of Taigum Square at an 18.8% premium to book value.
UBS raises FY27-FY29 FFO forecasts by 0.3%-0.6% and believes the portfolio deserves a higher valuation multiple, but sees limited further re-rating potential following recent share price outperformance.
The broker downgrades to Neutral from Buy and raises the target to $2.70 from $2.65.
Target price is $2.70 Current Price is $2.62 Difference: $0.08
If VCX meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $2.59, suggesting downside of -1.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 13.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.7, implying annual growth of -48.0%. Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 14.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.3, implying annual growth of 3.8%. Current consensus DPS estimate is 13.9, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 16.1. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
VMM VIRIDIS MINING AND MINERALS LIMITED
Rare Earth Minerals
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.35
Ord Minnett rates VMM as Speculative Buy (1) -
Ord Minnett maintains its Speculative Buy rating and raises its target for Viridis Mining and Minerals to $6.50 from $6.00 following delivery of the Colossus definitive feasibility study and US$140m of agreed equity funding.
Commentary suggests the funding should cover the equity component of the -US$449m development, while front-loaded production increases near-term earnings and valuation.
Forecasts were revised to reflect the feasibility study. Ord Minnett lines up a binding Solvay offtake, debt funding and permitting as the next catalysts, with construction and financing the main risks.
Target price is $6.50 Current Price is $4.35 Difference: $2.15
If VMM meets the Ord Minnett target it will return approximately 49% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.63
Morgans rates WHC as Downgrade to Hold from Buy (3) -
It is Morgans' view that Whitehaven Coal delivered a mixed FY26 result, with EBITDA broadly in line with consensus expectations while underlying NPAT missed slightly, constrained by the significant headwind of poor coal prices experienced during the first half.
A final dividend of 6.0c was declared, matching consensus expectations.
FY27 guidance proved softer than expected due to limited production growth and higher cost and capital expenditure expectations.
Reflecting recent share price strength, updated valuations, and a reduced target price of $8.05 (previously $8.50), Morgans moves its recommendation for Whitehaven Coal to a Hold rating from Buy.
Target price is $8.05 Current Price is $7.75 Difference: $0.3
If WHC meets the Morgans target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $8.23, suggesting upside of 6.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 24.00 cents and EPS of 45.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 46.5, implying annual growth of -4.3%. Current consensus DPS estimate is 15.9, implying a prospective dividend yield of 2.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 26.00 cents and EPS of 48.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 48.7, implying annual growth of 4.7%. Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 15.9. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.05
Macquarie rates ZIP as Outperform (1) -
Zip Co's FY26 cash EBITDA surged 57.9% y/y, driven by strong growth in both the US and A&NZ, alongside expanding margins and well-controlled bad debts.
Macquarie highlights US TTV growth of 42.5% in USD terms and a near doubling of A&NZ cash EBITDA, while FY27 guidance for $340m in group cash EBITDA was ahead of market expectations.
The broker sees continued upside from US growth, improving profitability and lower funding costs, lifting FY27-FY29 EPS forecasts by 4%, 2% and 2%, respectively.
The analyst sees the Outperform rating is supported by Zip's growth prospects and attractive unit economics, with the target raised to $3.50 from $3.40.
Target price is $3.50 Current Price is $2.57 Difference: $0.93
If ZIP meets the Macquarie target it will return approximately 36% (excluding dividends, fees and charges).
Current consensus price target is $3.99, suggesting upside of 55.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.9, implying annual growth of 51.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 15.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.3, implying annual growth of 24.5%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates ZIP as Buy (1) -
Ord Minnett maintains Zip Co on Buy and increases its target to $4.20 from $4.00 after FY26 cash EBITDA of $268.9m and FY27 guidance of $340m exceeded expectations.
US transaction volumes are expected to grow more than 30%, supported by customer growth, Pay-in-2 expansion and stable bad debts of 1.5%–2.0%.
The broker raises its FY27 cash EBITDA forecast by 9% to $341.4m.
Target price is $4.20 Current Price is $2.57 Difference: $1.63
If ZIP meets the Ord Minnett target it will return approximately 63% (excluding dividends, fees and charges).
Current consensus price target is $3.99, suggesting upside of 55.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.9, implying annual growth of 51.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 0.00 cents and EPS of 17.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.3, implying annual growth of 24.5%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates ZIP as Buy (1) -
UBS has increased confidence in Zip Co's execution through FY27 following a better than expected outlook, raising FY27-FY29 cash EBITDA forecasts by an average 11% on stronger US growth, improved funding costs and operating efficiencies.
The broker now expects 30% US TTV growth in FY27 and sees defensive qualities in the business, noting 65%-70% of US TTV is non-discretionary, while bad debts are expected to remain within the company's 1.5%-2% target range.
UBS also sees medium-term upside from potential new products under development, including Income Smoothing, All Access Card and Rent.
A Buy rating is reiterated. Target rises 15% to $4.70.
Target price is $4.70 Current Price is $2.57 Difference: $2.13
If ZIP meets the UBS target it will return approximately 83% (excluding dividends, fees and charges).
Current consensus price target is $3.99, suggesting upside of 55.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.9, implying annual growth of 51.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 18.5. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 0.00 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.3, implying annual growth of 24.5%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 14.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Today's Price Target Changes
| Company | Last Price | Broker | New Target | Prev Target | Change | |
| AFG | Australian Finance Group | $1.60 | Citi | 1.73 | 1.83 | -5.46% |
| Macquarie | 2.35 | 2.26 | 3.98% | |||
| AOV | Amotiv | $6.70 | Citi | 7.06 | 6.70 | 5.37% |
| APA | APA Group | $10.52 | Macquarie | 10.50 | 10.41 | 0.86% |
| Ord Minnett | 9.10 | 8.30 | 9.64% | |||
| UBS | 8.50 | 8.00 | 6.25% | |||
| ARF | Arena REIT | $2.49 | UBS | 2.71 | 3.92 | -30.87% |
| AVH | Avita Medical | $2.79 | Bell Potter | 3.70 | 2.10 | 76.19% |
| BGA | Bega Cheese | $6.49 | Bell Potter | 8.05 | 7.75 | 3.87% |
| Morgans | 7.05 | 6.50 | 8.46% | |||
| Ord Minnett | 6.30 | 5.70 | 10.53% | |||
| BXB | Brambles | $19.08 | Citi | 22.75 | 22.80 | -0.22% |
| Macquarie | 19.00 | 18.60 | 2.15% | |||
| Morgans | 18.60 | 18.70 | -0.53% | |||
| Ord Minnett | 24.40 | 24.50 | -0.41% | |||
| UBS | 24.50 | 24.30 | 0.82% | |||
| CCL | Cuscal | $5.92 | Bell Potter | 6.50 | 5.80 | 12.07% |
| Ord Minnett | 6.44 | 5.51 | 16.88% | |||
| CDA | Codan | $49.02 | UBS | 48.00 | 42.50 | 12.94% |
| CKF | Collins Foods | $8.00 | Citi | 8.80 | 10.30 | -14.56% |
| CWY | Cleanaway Waste Management | $2.63 | Morgan Stanley | 3.10 | 2.91 | 6.53% |
| DOW | Downer EDI | $6.59 | UBS | 7.20 | 8.00 | -10.00% |
| DXS | Dexus | $5.74 | Macquarie | 6.71 | 7.06 | -4.96% |
| UBS | 6.38 | 6.12 | 4.25% | |||
| EOL | Energy One | $17.11 | Bell Potter | 19.10 | 17.10 | 11.70% |
| FMG | Fortescue | $17.75 | Bell Potter | 17.10 | 17.40 | -1.72% |
| Morgans | 18.70 | 21.80 | -14.22% | |||
| Ord Minnett | 19.50 | 20.00 | -2.50% | |||
| UBS | 18.35 | 19.05 | -3.67% | |||
| GMD | Genesis Minerals | $8.32 | UBS | 9.80 | 9.50 | 3.16% |
| GMG | Goodman Group | $27.27 | Bell Potter | 32.65 | 33.95 | -3.83% |
| Ord Minnett | 28.25 | 29.50 | -4.24% | |||
| UBS | 33.66 | 34.09 | -1.26% | |||
| GQG | GQG Partners | $1.43 | UBS | 1.90 | 1.95 | -2.56% |
| HMY | Harmoney | $0.80 | Ord Minnett | 1.42 | 1.48 | -4.05% |
| HSN | Hansen Technologies | $3.26 | Morgan Stanley | 3.20 | 6.00 | -46.67% |
| IPH | IPH Ltd | $3.60 | Macquarie | 3.65 | 3.74 | -2.41% |
| Morgans | 4.65 | 5.39 | -13.73% | |||
| JHX | James Hardie Industries | $42.84 | Citi | 42.60 | 49.80 | -14.46% |
| LIC | Lifestyle Communities | $5.50 | UBS | 5.70 | 5.50 | 3.64% |
| MAF | MA Financial | $6.84 | Morgans | 8.66 | 8.56 | 1.17% |
| Ord Minnett | 9.15 | 8.90 | 2.81% | |||
| UBS | 10.10 | 9.30 | 8.60% | |||
| MGH | Maas Group | $5.82 | Macquarie | 6.75 | 6.30 | 7.14% |
| Morgans | 7.75 | 7.30 | 6.16% | |||
| MP1 | Megaport | $18.38 | Morgan Stanley | 25.00 | 12.50 | 100.00% |
| UBS | 26.40 | 24.20 | 9.09% | |||
| MPL | Medibank Private | $4.95 | Citi | 5.00 | 5.10 | -1.96% |
| UBS | 5.00 | 5.15 | -2.91% | |||
| NST | Northern Star Resources | $23.97 | Macquarie | 22.50 | 23.00 | -2.17% |
| Ord Minnett | 19.70 | 20.30 | -2.96% | |||
| UBS | 24.25 | 24.05 | 0.83% | |||
| NWH | NRW Holdings | $8.20 | Macquarie | 8.60 | 8.30 | 3.61% |
| Morgans | 8.80 | 8.00 | 10.00% | |||
| UBS | 8.50 | 7.95 | 6.92% | |||
| QAL | Qualitas | $3.22 | Macquarie | 4.15 | 3.95 | 5.06% |
| RDX | Redox | $3.29 | Morgan Stanley | 3.90 | 4.00 | -2.50% |
| Ord Minnett | 3.75 | 3.30 | 13.64% | |||
| UBS | 4.00 | 4.20 | -4.76% | |||
| RIC | Ridley Corp | $2.72 | UBS | 3.25 | 3.20 | 1.56% |
| SHL | Sonic Healthcare | $21.08 | Bell Potter | 27.50 | 28.75 | -4.35% |
| Morgans | 22.40 | 28.64 | -21.79% | |||
| Ord Minnett | 20.80 | 21.50 | -3.26% | |||
| UBS | 21.20 | 19.60 | 8.16% | |||
| SLC | Superloop | $3.06 | Morgans | 3.40 | 3.10 | 9.68% |
| SUL | Super Retail | $13.35 | Citi | 16.20 | 14.20 | 14.08% |
| Morgan Stanley | 11.90 | 11.20 | 6.25% | |||
| Morgans | 15.20 | 12.30 | 23.58% | |||
| Ord Minnett | 17.50 | 16.00 | 9.38% | |||
| UBS | 14.25 | 13.25 | 7.55% | |||
| TLC | Lottery Corp | $5.20 | Morgans | 5.60 | 5.80 | -3.45% |
| TPW | Temple & Webster | $4.30 | Bell Potter | 4.50 | 7.00 | -35.71% |
| UNI | Universal Store | $8.34 | Bell Potter | 9.70 | 9.30 | 4.30% |
| Citi | 12.96 | 9.80 | 32.24% | |||
| Morgans | 10.20 | 9.50 | 7.37% | |||
| UBS | 9.25 | 9.00 | 2.78% | |||
| VCX | Vicinity Centres | $2.62 | Macquarie | 2.37 | 2.30 | 3.04% |
| Ord Minnett | 2.55 | 2.50 | 2.00% | |||
| UBS | 2.70 | 2.65 | 1.89% | |||
| VMM | Viridis Mining and Minerals | $4.35 | Ord Minnett | 6.50 | 6.00 | 8.33% |
| WHC | Whitehaven Coal | $7.75 | Morgans | 8.05 | 8.50 | -5.29% |
| ZIP | Zip Co | $2.57 | Macquarie | 3.50 | 3.40 | 2.94% |
| Ord Minnett | 4.20 | 4.00 | 5.00% | |||
| UBS | 4.70 | 4.10 | 14.63% |
Summaries
| A1N | ARN Media | Sell - UBS | Overnight Price $0.26 |
| AAI | Alcoa | Buy - Citi | Overnight Price $72.91 |
| AFG | Australian Finance Group | Neutral - Citi | Overnight Price $1.60 |
| Outperform - Macquarie | Overnight Price $1.60 | ||
| AIA | Auckland International Airport | Neutral - Citi | Overnight Price $7.29 |
| Outperform - Macquarie | Overnight Price $7.29 | ||
| APA | APA Group | Buy - Citi | Overnight Price $10.19 |
| Outperform - Macquarie | Overnight Price $10.19 | ||
| Lighten - Ord Minnett | Overnight Price $10.19 | ||
| Sell - UBS | Overnight Price $10.19 | ||
| ARF | Arena REIT | Neutral - UBS | Overnight Price $2.42 |
| ASG | Autosports Group | Outperform - Macquarie | Overnight Price $1.50 |
| AVH | Avita Medical | Speculative Buy - Bell Potter | Overnight Price $2.82 |
| AX1 | Accent Group | Neutral - Citi | Overnight Price $0.79 |
| BGA | Bega Cheese | Buy - Bell Potter | Overnight Price $6.66 |
| Downgrade to Hold from Accumulate - Morgans | Overnight Price $6.66 | ||
| Hold - Ord Minnett | Overnight Price $6.66 | ||
| BXB | Brambles | Buy - Citi | Overnight Price $18.80 |
| Neutral - Macquarie | Overnight Price $18.80 | ||
| Hold - Morgans | Overnight Price $18.80 | ||
| Buy - Ord Minnett | Overnight Price $18.80 | ||
| Buy - UBS | Overnight Price $18.80 | ||
| CCL | Cuscal | Buy - Bell Potter | Overnight Price $5.62 |
| Buy - Ord Minnett | Overnight Price $5.62 | ||
| CDA | Codan | Neutral - UBS | Overnight Price $48.88 |
| CHC | Charter Hall | Buy - Citi | Overnight Price $22.11 |
| Buy - UBS | Overnight Price $22.11 | ||
| CKF | Collins Foods | Neutral - Citi | Overnight Price $7.99 |
| CWY | Cleanaway Waste Management | No Rating - Macquarie | Overnight Price $2.60 |
| Downgrade to Equal-weight from Overweight - Morgan Stanley | Overnight Price $2.60 | ||
| DOW | Downer EDI | Neutral - UBS | Overnight Price $6.68 |
| DXS | Dexus | Outperform - Macquarie | Overnight Price $5.89 |
| Neutral - UBS | Overnight Price $5.89 | ||
| EOL | Energy One | Buy - Bell Potter | Overnight Price $16.54 |
| FMG | Fortescue | Hold - Bell Potter | Overnight Price $17.95 |
| Underweight - Morgan Stanley | Overnight Price $17.95 | ||
| Hold - Morgans | Overnight Price $17.95 | ||
| Accumulate - Ord Minnett | Overnight Price $17.95 | ||
| Neutral - UBS | Overnight Price $17.95 | ||
| FPH | Fisher & Paykel Healthcare | Neutral - Citi | Overnight Price $35.74 |
| GMD | Genesis Minerals | Buy - Citi | Overnight Price $8.01 |
| Buy - UBS | Overnight Price $8.01 | ||
| GMG | Goodman Group | Downgrade to Hold from Buy - Bell Potter | Overnight Price $28.78 |
| Outperform - Macquarie | Overnight Price $28.78 | ||
| Hold - Ord Minnett | Overnight Price $28.78 | ||
| Buy - UBS | Overnight Price $28.78 | ||
| GQG | GQG Partners | Buy - UBS | Overnight Price $1.49 |
| GYG | Guzman y Gomez | Sell - Citi | Overnight Price $23.97 |
| Neutral - UBS | Overnight Price $23.97 | ||
| HMY | Harmoney | Buy - Ord Minnett | Overnight Price $0.77 |
| HSN | Hansen Technologies | Downgrade to Underweight from Overweight - Morgan Stanley | Overnight Price $3.22 |
| IPH | IPH Ltd | Neutral - Macquarie | Overnight Price $3.75 |
| Buy - Morgans | Overnight Price $3.75 | ||
| JHX | James Hardie Industries | Buy - Citi | Overnight Price $42.80 |
| Outperform - Macquarie | Overnight Price $42.80 | ||
| LIC | Lifestyle Communities | Neutral - Citi | Overnight Price $5.34 |
| Neutral - UBS | Overnight Price $5.34 | ||
| MAF | MA Financial | Buy - Morgans | Overnight Price $7.10 |
| Buy - Ord Minnett | Overnight Price $7.10 | ||
| Buy - UBS | Overnight Price $7.10 | ||
| MGH | Maas Group | Outperform - Macquarie | Overnight Price $6.17 |
| Buy - Morgans | Overnight Price $6.17 | ||
| MLG | MLG Oz | Speculative Buy - Morgans | Overnight Price $0.82 |
| MP1 | Megaport | Buy - Citi | Overnight Price $19.31 |
| Upgrade to Overweight from Equal-weight - Morgan Stanley | Overnight Price $19.31 | ||
| Buy - UBS | Overnight Price $19.31 | ||
| MPL | Medibank Private | Neutral - Citi | Overnight Price $4.71 |
| Buy - Ord Minnett | Overnight Price $4.71 | ||
| Neutral - UBS | Overnight Price $4.71 | ||
| NOU | Noumi | Hold - Bell Potter | Overnight Price $0.12 |
| NST | Northern Star Resources | Neutral - Macquarie | Overnight Price $23.94 |
| Downgrade to Hold from Accumulate - Morgans | Overnight Price $23.94 | ||
| Hold - Ord Minnett | Overnight Price $23.94 | ||
| Buy - UBS | Overnight Price $23.94 | ||
| NWH | NRW Holdings | Outperform - Macquarie | Overnight Price $7.59 |
| Accumulate - Morgans | Overnight Price $7.59 | ||
| Buy - UBS | Overnight Price $7.59 | ||
| PPM | Pepper Money | Buy - Citi | Overnight Price $1.81 |
| PWH | PWR Holdings | Neutral - UBS | Overnight Price $10.52 |
| QAL | Qualitas | Buy - Citi | Overnight Price $3.34 |
| Outperform - Macquarie | Overnight Price $3.34 | ||
| RDX | Redox | Equal-weight - Morgan Stanley | Overnight Price $3.59 |
| Accumulate - Ord Minnett | Overnight Price $3.59 | ||
| Buy - UBS | Overnight Price $3.59 | ||
| RIC | Ridley Corp | Buy - UBS | Overnight Price $2.90 |
| RSG | Resolute Mining | Outperform - Macquarie | Overnight Price $1.26 |
| SHL | Sonic Healthcare | Buy - Bell Potter | Overnight Price $21.38 |
| Neutral - Citi | Overnight Price $21.38 | ||
| Underweight - Morgan Stanley | Overnight Price $21.38 | ||
| Downgrade to Hold from Buy - Morgans | Overnight Price $21.38 | ||
| Hold - Ord Minnett | Overnight Price $21.38 | ||
| Neutral - UBS | Overnight Price $21.38 | ||
| SKC | SkyCity Entertainment | Outperform - Macquarie | Overnight Price $0.51 |
| SLC | Superloop | Hold - Morgans | Overnight Price $3.13 |
| SPK | Spark New Zealand | Outperform - Macquarie | Overnight Price $1.82 |
| Buy - UBS | Overnight Price $1.82 | ||
| SUL | Super Retail | Buy - Citi | Overnight Price $14.45 |
| Underweight - Morgan Stanley | Overnight Price $14.45 | ||
| Hold - Morgans | Overnight Price $14.45 | ||
| Upgrade to Buy from Hold - Ord Minnett | Overnight Price $14.45 | ||
| Neutral - UBS | Overnight Price $14.45 | ||
| TCL | Transurban Group | Neutral - Citi | Overnight Price $13.96 |
| TLC | Lottery Corp | Hold - Morgans | Overnight Price $5.20 |
| TLX | Telix Pharmaceuticals | Buy - Bell Potter | Overnight Price $17.38 |
| Buy, High Risk - Citi | Overnight Price $17.38 | ||
| Overweight - Morgan Stanley | Overnight Price $17.38 | ||
| TPG | TPG Telecom | Neutral - UBS | Overnight Price $3.53 |
| TPW | Temple & Webster | Downgrade to Hold from Buy - Bell Potter | Overnight Price $4.51 |
| TTX | Tetratherix | Buy - Morgans | Overnight Price $6.10 |
| UNI | Universal Store | Buy - Bell Potter | Overnight Price $8.30 |
| Buy - Citi | Overnight Price $8.30 | ||
| Buy - Morgans | Overnight Price $8.30 | ||
| Buy - UBS | Overnight Price $8.30 | ||
| VCX | Vicinity Centres | Neutral - Macquarie | Overnight Price $2.61 |
| Hold - Ord Minnett | Overnight Price $2.61 | ||
| Downgrade to Neutral from Buy - UBS | Overnight Price $2.61 | ||
| VMM | Viridis Mining and Minerals | Speculative Buy - Ord Minnett | Overnight Price $4.35 |
| WHC | Whitehaven Coal | Downgrade to Hold from Buy - Morgans | Overnight Price $7.63 |
| ZIP | Zip Co | Outperform - Macquarie | Overnight Price $3.05 |
| Buy - Ord Minnett | Overnight Price $3.05 | ||
| Buy - UBS | Overnight Price $3.05 |
RATING SUMMARY
| Rating | No. Of Recommendations |
| 1. Buy | 63 |
| 2. Accumulate | 3 |
| 3. Hold | 46 |
| 4. Reduce | 1 |
| 5. Sell | 7 |
Saturday 22 August 2026
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
| 1 |
The Market In Numbers – 21 Nov 2026Nov 21 2026 - Australia |
| 2 |
ASX Winners And Losers Of Today – 20-11-26Nov 20 2026 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 20-11-2026Nov 20 2026 - Australia |
| 4 |
Next Week At A Glance – 23-27 Nov 2026Nov 20 2026 - Weekly Reports |
| 5 |
Weekly Top Ten News Stories – 20 November 2026Nov 20 2026 - Weekly Reports |

